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1.1 INTRODUCTION 
Oral route has been the commonly adopted and most convenient route for drug 
delivery. Oral route of administration has been received more attention in the 
pharmaceutical field because of the more flexibility in the designing of dosage form 
than drug delivery design for other routes, ease of administration as well as traditional 
belief that by oral administration the drug is well absorbed as the food stuffs that are 
ingested daily. Pharmaceutical products designed for oral delivery are mostly the 
immediate release types which are designed for immediate release of drug for rapid 
absorption.  The term drug delivery covers a very broad range of techniques used to 
get therapeutic agents in to human body. The limitations of the most obvious and 
trusted drug delivery techniques those of the ingested tablet and of the intravenous/ 
intramuscular/ subcutaneous injections have been recognized for some time. The 
former delivers drug in to the blood only through the hepatic system and hence the 
amount in the blood stream may be much lower than the amount formulated into the 
tablet. Further more liver damage is the unfortunate side effect of many soluble 
tableted drug 
[3]
. 
To over come some of these limitations, other modes of drug delivery in to the 
body were investigated. Those are  
1. Trans Dermal Drug Delivery System (through the intact skin) 
2. Trans Mucosal Drug Delivery System (through the intact mucosa of the 
mouth, intestine, rectum, vagina or nose) 
3. Trans Ocular Drug Delivery System (through the eye) 
4. Trans Alveolar Drug Delivery System (inhalation through the lung tissue) 
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5. Implantable Drug Delivery System (through the subcutaneous and deeper 
implants, deliver into surrounding tissue) 
6. Injectables (I.M or Subcutaneous) 
Of the above modes, Transdermal, Transmucosal, Injectables and 
Subcutaneous Implants have been found varying degree of commercial acceptance
 [3]
. 
TRANSMUCOSAL DRUG DELIVEY SYSTEM 
[2]
 
Delivery of drugs through the absorptive mucosa in various easily accessible 
body cavities, like the Buccal, ocular, nasal, rectal, and vaginal mucosae, has the 
advantage of bypassing the hepatic-gastrointestinal first pass elimination associated 
with oral administration. Further more, because of the dual biophysical and 
biochemical nature of these mucosal membranes, drugs with hydrophilic and/or 
hydrophobic characteristics can be readily absorbed.  
Different types of transmucosal drug delivery systems are 
 Buccal Drug Delivery System. 
 Ocular Drug Delivery System. 
 Vaginal Drug Delivery System. 
 Rectal Drug Delivery System. 
 Nasal Drug Delivery System. 
 Gastro Intestinal Drug Delivery System. 
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BUCCAL DRUG DELIVERY SYSTEM 
[1]
 
The mucosa of the mouth is very different from the rest of the gastrointestinal 
tract and morphologically is more similar to skin. Although the permeability of skin is 
widely regarded as poor, it is not generally appreciated that the oral mucosa lacks the 
good permeability demonstrated by the intestine. These differences within the 
gastrointestinal tract can largely be attributed to the organization of the epithelia, 
which serve very different functions. A simple, single-layered epithelium lines the 
stomach, small intestine, and colon, which provides for a Minimal transport distance 
for absorbents. In contrast, a stratified or multilayered epithelium covers the oral 
cavity and esophagus and, in common with skin, is composed of layers with varying 
states of differentiation or maturation evident on progression from the basal cell layer 
to the surface. Drugs have been applied to the oral mucosa for topical applications for 
many years. However, recently there has been interest in exploiting the oral cavity as 
a portal for delivering drugs to the systemic circulation. Notwithstanding the 
relatively poor permeability characteristics of the epithelium, a number of advantages 
are offered by this route of administration. Foremost among these are the avoidance of 
first-pass metabolism, ease of access to the delivery site, and the opportunity of 
sustained drug delivery predominantly via the buccal tissues. Delivery can also be 
terminated relatively easily if required. The robustness of the epithelium necessary to 
withstand mastication also serves the drug delivery process well as fast cellular 
recovery follows local stress and damage. Indeed the two most challenging issues to 
be addressed in the oral mucosal delivery of drugs are undoubtedly permeability 
enhancement and dosage form retention at the site of application. The continuous 
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secretion of saliva and its subsequent swallowing can lead to substantial drug 
depletion from the dosage form and hence low bioavailability
 [1]
.  
Advantages
 [4]
 
• The oral mucosa has a rich blood supply. Drugs are absorbed from the oral 
cavity through the oral mucosa, and transported through the deep lingual or 
facial vein, internal jugular vein and braciocephalic vein into the systemic 
circulation. Following buccal administration, the drug gains direct entry into 
the systemic circulation thereby bypassing the first pass effect. 
• It is richly vascularized and more accessible for administration and removal of 
dosage forms. 
• No hepatic first-pass effect. 
• No pre-systemic metabolism in the gastrointestinal tract. 
• Ease of administration 
• High patient accessibility. 
• An expanse of smooth muscle and relatively immobile mucosa, suitable for 
administration of retentive dosage forms. 
• Bypass exposure of the drugs to the gastrointestinal fluids. 
• More rapid cellular recovery and achievement of a localized site on smooth 
surface of buccal mucosa. 
• Low enzyme activity, suitability for drugs/ excipients that mildly and 
reversibly damages or irritates the mucosa. 
• The oral mucosa is routinely exposed to a multitude of different foreign 
compounds. So it has evolved a robust membrane that is less prone to 
irreversible damage by drug, dosage form or additiv
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• Non-invasive method of drug administration. 
• Facility to include permeation enhancer or enzyme inhibitor or pH modifier in 
the formulation. 
Disadvantages 
• Low permeability of buccal membrane specifically when compared to the 
sublingual membrane. 
• Small surface area (170 cm2). 
• Saliva (0.5–2 L/day) is continuously secreted into the oral cavity diluting 
drugs at the site of absorption resulting in low drug concentrations at the 
surface of the absorbing membrane. 
• Inconvenience of patient when eating or drinking. 
Limitations in buccal absorption 
• The area of absorptive membrane is relatively smaller. 
• Drugs, which are unstable at buccal pH cannot be administered by this route. 
• Only drugs with a small dose requirement can be administered. 
•  Only those drugs, which are absorbed by passive diffusion, can be 
administered by this route. 
•  Eating and drinking may become restricted. 
• There is an ever present possibility of the patient swallowing the tablet. 
• Over hydration may lead to the formation of slippery surface and structural 
integrity of the formulation may get disrupted by this swelling and hydration 
of the buccoadhesive polymers. 
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ANATOMY AND PHYSIOLOGY OF THE ORAL MUCOSA
 [5, 6]
  
Structure 
The oral mucosa is anatomically divided into three tissue layers. 
 These three layers are the 1) epithelium; 2) basement membrane; and 3) connective 
tissues. 
 
Fig.No.1: Schematic diagram showing the principal components of oral mucosa. 
Epithelium 
The epithelium consists of approximately 40–50 layers of stratified squamous 
epithelial cells. The epithelial cells originate from a layer of basal cells, which are 
cuboidal in shape, undergo continuous mitosis, and move to the surface. As the cells 
migrate to the surface through the intermediate layers, they differentiate and become 
larger, flattened, and surrounded by an external lipid matrix (membrane-coating 
granules). This external lipid matrix determines the drug permeability of the tissue. 
Although gingiva (gum) and the hard palate are keratinized, areas such as buccal, 
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sublingual, and the soft palate are non-keratinized. The thickness of buccal epithelium 
varies with location and typically ranges from 500 to 800 mm in humans, dogs, and 
rabbits. The estimated cell turnover time is 5–6 days. In addition, the buccal 
epithelium is also characterized by the presence of intercellular gap junctions. 
Basement membrane 
The basement membrane (BM) is a continuous layer of extracellular materials 
and forms a boundary between the basal layer of epithelium and the connective 
tissues of the lamina propria and the sub mucosa. The BM can be subdivided into the 
a) lamina lucida, b) lamina densa, and c) a sub layer of fibrous material. The functions 
of the BM include providing  
1) Adherence between epithelium and underlying connective tissues 
2) Mechanical support for epithelium 
3) A barrier to the passage of cells and some large molecules. 
Connective tissues 
Connective tissues consist of lamina propria and sub mucosa, if present. The 
lamina propria is a continuous sheet of connective tissue composed of blood 
capillaries and nerve fibers serving the oral mucosa. Vascular drainage from the oral 
mucosa is principally by way of the lingual, facial, and retromandibular veins. These 
veins open into the internal jugular vein and thus avoid first-pass metabolism. The 
buccal mucosae from monkeys, apes, dogs, pigs, and rabbits possess physiology very 
similar to that of human buccal mucosa. 
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Permeability 
Permeability barriers 
The permeability of buccal mucosa lies somewhat between the skin epidermis 
and intestinal mucosa. Epithelium the predominant barrier to drug diffusion resides 
approximately within the outermost one-third of the epithelium. This is true of both 
keratinized and nonkeratinized epithelia. Therefore, keratinization is unlikely to offer 
major resistance to buccal permeation. Membrane Coating Granules (MCG), MCGs 
are spherical or oval organelles (100–300 nm in diameter) found both in keratinized 
as well as in non-keratinized epithelia but are different with regard to composition in 
both epithelia. MCGs discharge their contents into the intercellular space and thus 
form the permeability barrier. 
BIOADHESION AND MUCOADHESION 
[4] 
The term bioadhesion can be defined as the state in which two materials, at 
least one biological in nature, are held together for an extended period of time by 
interfacial forces, in biological systems, bioadhesion can be classified into 3 types: 
• Type 1, adhesion between two biological phases, for example, platelet 
aggregation and wound healing. 
• Type 2, adhesion of a biological phase to an artificial substrate, for example, 
cell adhesion to culture dishes and biofilm formation on prosthetic devices and 
inserts. 
• Type 3, adhesion of an artificial material to a biological substrate, for 
example, adhesion of synthetic hydrogels to soft tissues and adhesion of 
sealants to dental enamel. 
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For drug delivery purposes, the term bioadhesion implies attachment of a drug 
carrier system to a specified biological location. The biological surface can be 
epithelial tissue or the mucus coat on the surface of a tissue. If adhesive attachment is 
to a mucus coat, the phenomenon is referred to as mucoadhesion. Leung and 
Robinson described mucoadhesion as the interaction between a mucin surface and a 
synthetic or natural polymer. Mucoadhesion should not be confused with bioadhesion, 
in bioadhesion, the polymer is attached to the biological membrane and if the 
substrate is mucus membrane the term mucoadhesion is used. 
THEORIES OF MUCOADHESION
 [4]
: 
Various theories exist to explain at least some of the experimental 
observations made during the bioadhesion process. Unfortunately, each theoretical 
model can only explain a limited number of the diverse range of interactions that 
constitute the bioadhesive bond. However, four main theories can be distinguished. 
Wetting Theory of Mucoadhesion: 
The wetting theory is perhaps the oldest established theory of adhesion. It is 
best applied to liquid or low-viscosity bioadhesives. It explains adhesion as an 
embedding process, whereby adhesive agents penetrate into surface irregularities of 
the substrate and ultimately harden, producing many adhesive anchors. Free 
movement of the adhesive on the surface of the substrate means that it must overcome 
any surface tension effects present at the interface. The wetting theory calculates the 
contact angle and the thermodynamic work of adhesion. 
The work done is related to the surface tension of both the adhesive and the 
substrate, as given by Dupre’s equation.                                
                             ------ (1) 
Chapter-1                                                                                                                  Introduction 
 
	
Dept. of Pharmaceutics, The Erode College of Pharmacy & Research Institute  


Where A is the specific thermodynamic work of adhesion and b, , and bt 
represent, respectively, the surface tensions of the bioadhesive polymer, the substrate, 
and the interfacial tension. The adhesive work done is a sum of the surface tensions of 
the two adherent phases, less the interfacial tensions apparent between both phases.  
Horizontal resolution of the forces gives the Young equation: 
                                               -------- (2) 
Where  is the angle of contact, bt is the surface tension between the tissue 
and polymer, ba is the surface tension between polymer and air, and ta is the surface 
tension between tissue and air. Equation 3 states that if the angle of contact,  is 
greater than zero, the wetting will be incomplete. If the vector ta greatly exceeds bt + 
ba, that is: 
                                                -------- (3) 
Then  will approach zero and wetting will be complete. If a bioadhesive 
material is to successfully adhere to a biological surface, it must first dispel barrier 
substances and then spontaneously spread across the underlying substrate, either 
tissue or mucus. The spreading coefficient, Sb, can be defined as shown in Equation 4: 
                                  ------------ (4) 
This states that bioadhesion is successful if Sb is positive, thereby setting the 
criteria for the surface tension vectors. In other words, bioadhesion is favored by large 
values of ta or by small values of bt and ba. 
Electrostatic Theory of Mucoadhesion: 
According to electrostatic theory, transfer of electrons occurs across the 
adhesive interface and adhering surface. This results in the establishment of the 
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electrical double layer at the interface and a series of attractive forces responsible for 
maintaining contact between the two layers. 
Diffusion Theory of Mucoadhesion: 
Diffusion theory describes that polymeric chains from the bioadhesive 
interpenetrate into glycoprotein mucin chains and reach a sufficient depth within the 
opposite matrix to allow formation of a semi permanent bond. The process can be 
visualized from the point of initial contact. The existence of concentration gradients 
will drive the polymer chains of the bioadhesive into the mucus network and the 
glycoprotein mucin chains into the bioadhesive matrix until an equilibrium 
penetration depth is achieved. 
The exact depth needed for good bioadhesive bonds is unclear, but is 
estimated to be in the range of 0.2–0.5 m. The mean diffusional depth of the 
bioadhesive polymer segments, s, may be represented by Equation 5 
                                                    ------------ (5) 
 
Where D is the diffusion coefficient and t is the contact time. Duchene adapted 
Equation 5 to give Equation 6, which can be used to determine the time, t, to 
bioadhesion of a particular polymer: 
                                                                 ------------ (6) 
In which l represents the interpenetrating depth and Db the diffusion 
coefficient of a bioadhesive through the substrate. 
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Once intimate contact is achieved, the substrate and adhesive chains move 
along their respective concentration gradients into the opposite phases. Depth of 
diffusion is dependent on the diffusion coefficient of both phases. Reinhart and 
Peppas reported that the diffusion coefficient depended on the molecular weight of the 
polymer strand and that it decreased with increasing cross-linking density. 
Adsorption Theory of Mucoadhesion: 
According to the adsorption theory, after an initial contact between two 
surfaces, the materials adhere because of surface forces acting between the chemical 
structures at the two surfaces. When polar molecules or groups are present, they 
reorientate at the interface. Chemisorption can occur when adhesion is particularly 
strong. The theory maintains that adherence to tissue is due to the net result of one or 
more secondary forces (Vander Waal’s forces, hydrogen bonding, and hydrophobic 
bonding). 
Fracture Theory of Adhesion: 
This theory describes the force required for the separation of two surfaces after 
adhesion. The fracture strength is equivalent adhesive strength through the following 
equation. This theory is useful for the study of bioadhesion by tensile apparatus. 
                                                ----------- (7) 
Where  is the fracture strength, e Fracture energy, E young modulus of elasticity and 
L the critical crack length. 
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Measurement of Bioadhesion
 [5]
: 
Measurement of bioadhesion not only helps in screening the candidate 
polymer but also assists in studying the mechanism of bioadhesion. However, 
performance of the final dosage form containing the polymer and the drug is the best 
test for bioadhesion. 
In vitro measurements: 
Measurement of either tensile or shear stress is the most commonly used in 
vitro method to measure bioadhesion. All in vitro measurements provide a rank order 
of bioadhesive strength for a series of candidate polymers. Measurement of tensile 
strength involves quantitating the force required to break the adhesive bond between 
the test polymer and a model membrane. This method typically uses a modified 
balance or tensile tester. A section of freshly excised rabbit stomach tissue with the 
mucosal side exposed is secured on a weighed glass vial and placed in a beaker 
containing USP-simulated gastric fluid. Another section of the same tissue is secured 
onto a rubber stopper with a vial cap with the mucus side exposed. A small quantity 
of the test polymer is placed between the two mucosal tissues. The force required to 
detach the polymer from the tissue is then recorded. Measurement of shear strength 
involves quantitating the force that causes the polymer to slide in a direction parallel 
to the plane of contact between the polymer and the mucus. This method uses a glass 
plate suspended from a microbalance on which the test polymer is coated. This plate 
is then dipped in a temperature controlled mucus sample. The force required to pull 
the plate out of the mucus sample is determined under constant experimental 
conditions. Additional in vitro methods include adhesion weight, fluorescent probe, 
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flow channel, mechanical spectroscopic, falling film, colloidal gold staining, 
viscometric method, thumb test, adhesion number, and electrical conductance. 
 
Fig.No.2: The apparatus and the setup for assessing the tensile strength. 
In vivo measurements: 
In vivo methods are relatively few and measure the residence time of 
bioadhesives at the application site. Techniques such as g-scintigraphy, perfused 
intestinal loop and radio labeled transit studies using 55Cr-labeled bioadhesive 
polymer, and 99mTc-labeled polycarbophil have been used for this purpose. 
FACTORS AFFECTING SYSTEMIC ORAL MUCOSAL DELIVERY
 [5]
: 
Membrane Factors: 
Regional differences in both permeability and thickness affect both the rate 
and extent of drug reaching the systemic circulation. Keratinization and composition, 
although not major factors, of the various oral mucosae affect systemic mucosal drug 
delivery. Additional factors such as absorptive membrane thickness, blood supply, 
blood/lymph drainage, cell renewal rate, and enzyme content will also govern the rate 
and extent of drug absorption into the systemic circulation. 
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Environmental Factors: 
Saliva: 
A major portion of saliva is composed of water (99%) and has a p
H
 of 6.5–7.5 
depending on the flow rate and location. An increase in the salivary flow rate leads to 
the secretion of watery saliva. Stimulated salivary secretion affects the film thickness 
and aids in easy migration of test compounds from one region of the mouth to 
another. Salivary p
H
 is also important because passive diffusion of unionized drug is 
the major mechanism of oral absorption. 
Salivary glands: 
Drug-delivery systems, therefore, should not be placed either over a duct or 
adjacent to a salivary duct because this may dislodge the retentive system or may 
result in excessive washout of the drug or rapid dissolution/erosion of the delivery 
system, making it difficult to achieve high local drug concentrations. Also, if a 
retentive system is placed over salivary ducts, the reduced salivary flow rate may 
produce less/no mucus that is required for proper attachment of a mucoadhesive 
delivery device. 
Movement of the oral tissues: 
Talking, eating, and swallowing may cause some mouth movement leading to 
dislodgment of the delivery device. The movement of the tongue may also influence 
the delivery of drugs from a mucoadhesive, retentive system owing to the tongue 
swiping across the dosage form and adjacent tissues as well as to induction of suction 
pressures from the tongue compressing against the hard palate. 
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Permeant factors 
[6]
: 
The permeation of a drug molecule across the buccal mucosa is dependent on 
the following. 
1. Molecular size—for hydrophilic substances, as molecular weight and molecular 
size/radius ascends, permeability typically diminishes. Small molecular weight 
permeants (MW < 100 Da) are rapidly transported through buccal mucosa.  
2. Lipid solubility—for non-ionizable compounds, as the lipophilicity rises, the drug 
permeability typically increases. To maximize the absorption rate, a drug should be 
available in the salivary film at its solubility limit.  
3. Ionization—for ionizable drugs, maximal permeation occurs at the p
H
 at which 
ionization is least, i.e., where the drug is predominantly in the unionized form. The 
rate of drug absorption for the transcellular route is p
H
-dependent. Such dependency 
results from the fact that the membrane/aqueous partition coefficient for an ionizable 
drug is p
H
-dependent. Basement Membrane (BM). The BM has an enormous surface 
area compared with the epithelium owing to connective tissue papillae, which may 
affect the effective diffusional path length. 
 
FORMULATIONS FOR BUCCAL MUCOADHESIVE DRUG DELIVERY
 [5]
: 
Novel dosage forms such as adhesive tablets, patches, gels, and ointments 
have been developed primarily for systemic delivery of therapeutic agents. These 
dosage forms are also capable of providing sustained drug delivery. 
Buccal dosage forms can be of   1) reservoir type and     2) matrix type. 
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Reservoir type: 
Drug formulations of the reservoir type are surrounded by a polymeric 
membrane, which controls the release rate. Reservoir systems present a constant 
release profile, provided   1) the polymeric membrane is rate limiting and 2) an excess 
amount of drug is present in the reservoir. 
Matrix type: 
Drug is uniformly dispersed in the polymer in matrix type systems, and drug 
release is controlled by the matrix. Drug molecules dispersed in the polymer have to 
dissolve in the medium and then diffuse through the polymer network. Therefore, a 
drug dispersion and drug-depletion zone always exists in the matrix. A thin 
hydrodynamic diffusion layer also exists at the interface of the drug and the matrix.   
A matrix system may result in a constant release profile only at early times when the 
drug-depletion zone is rather insignificant. 
The parameters that determine the release rate of a drug from a delivery device 
include polymer solubility, polymer diffusivity, and thickness of the polymer 
diffusional path, and the drug’s aqueous solubility, partition coefficient, and aqueous 
diffusivity. Finally, the thickness of the hydrodynamic diffusion layer, the amount of 
drug loaded into the matrix, and the surface area of the device all affect the drug’s 
release rate. 
 
Buccal adhesive tablets: 
Adhesive tablets may be either monolithic or multilayered devices. Monolithic 
tablets can be prepared by conventional techniques of either direct compression or wet 
granulation. These tablets provide the possibility of holding large amounts of drug. 
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Using either compression or spray coating, a partial coating of every face except one 
that is in contact with the mucosa with a water-impermeable material such as 
cellophane, hydrogenated castor oil, Teflon, ethyl cellulose, etc., may cause 
unidirectional drug release. Multilayered tablets may be prepared by adding each 
formulation ingredient layer by layer into a die and by compressing it on a tablet 
press. These tablets can be designed to deliver drugs either systemically or locally. 
For multilayered tablets, incorporation of the drug into the adhesive layer, which is 
immediately adjacent to the mucosal surface, may aid in optimizing bioadhesion. 
Buccal adhesive patches: 
Adhesive patches may also be monolithic or multilayered devices of the 
reservoir or matrix type for either systemic or local drug delivery. Two primary types 
of manufacturing processes are usually used to prepare adhesive patches. These 
include solvent casting and direct milling (with or without a solvent). The 
intermediate product is a sheet from which patches are punched. A backing is then 
applied to control the direction of drug release and to minimize deformation and 
disintegration of the device during residence in the mouth. Preparation of adhesive 
patches by the solvent–casting method involves casting of appropriately prepared 
aqueous solutions of either polymer (for drug-free patches) or a drug/polymer mixture 
onto a backing layer sheet mounted on a stainless steel plate by means of a frame. 
Drying may then be performed by perfusing with a thermo stated stream of water or 
by air drying. The temperature is typically selected based on the excipients used in the 
formulation. On complete drying, the laminate may be cut into the desired shape and 
size using a suitable punch and a die set. Preparation of adhesive patches by direct 
milling is done by homogeneously mixing the drug and the bioadhesive, with or 
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without the aid of a solvent, using a two-roll mill. The polymer/drug mixture may 
then be compressed to its desired thickness, and patches of appropriate size may be 
cut or punched out. The polymer/drug mixture prepared with a solvent may require an 
additional drying step afforded by air or oven drying. 
 
Fig.No.3: The design of mucoadhesive buccal patch. 
In response to some of the drawbacks of tablets, different flexible, high-
surface area, adhesive films and laminated adhesive patches have been investigated 
for oral mucosal drug delivery. Different polymers can be used for the development of 
mucosal patches, including cellulose derivatives (e.g., methylcellulose, sodium 
carboxymethylcellulose, hydroxyethylcellulose), natural gums (guar gum, Karaya 
gum, agarose), and polyacrylates, including poly(acrylic acid), poly(methacrylic 
acid), poly(vinylpyrrolidone), poly(ethylene glycol), and gelatin. These polymers 
exhibit muccoadhesive properties and form adhesive hydrogels in the presence of 
saliva. 
 The adhesive part of the system can be used as drug carrier or as an adhesive 
for the retention of a drug loaded non adhesive layer. In this respect a peripheral 
adhesive ring could be casted. The use of an impermeable backing membrane will 
maximize the drug concentration gradient and prolong adhesion because the system is 
protected from saliva. 
Different types of drug release pattern from buccal patches 
 Bidirectional release from adhesive patch by  dissolution or diffusion; 
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 Unidirectional release from patch embedded in an adhesive shield; 
 Bidirectional release from a laminated patch; 
 Unidirectional release from a laminated patch. 
 
Fig.No.4: The geometric designs of buccal delivery devices. 
The concept of using buccal patches as a matrix for drug delivery is not new. 
Buccal dosage forms offer several advantages as a drug delivery system including 
local delivery, rapid buccal adsorption, rapid onset, prolonged drug release, dose 
termination and product line extension and future products are expected soon. 
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1.2 DISEASE PROFILE 
1.2.1 Introduction to emesis
 [15]
: 
Vomiting (known medically as emesis and informally as throwing up and by a 
number of other terms) is the forceful expulsion of the contents of one's stomach through the 
mouth and sometimes the nose. Vomiting can occur due to a wide variety of conditions; it 
may present as a specific response to ailments like gastritis or poisoning, or as a non-specific 
sequela of disorders ranging from brain tumors and elevated intracranial pressure to 
overexposure to ionizing radiation. The feeling that one is about to vomit is called nausea, 
which usually proceeds, but does not always lead to, vomiting. Antiemetic are sometimes 
necessary to suppress nausea and vomiting. In severe cases, where dehydration develops, 
intravenous fluid may be required. 
Types of vomiting: 
 Motion sickness 
 Morning sickness(vomiting during pregnancy) 
 Chemotherapy or radiation induced nausea and vomiting 
 Post operative vomiting 
 Vomiting of varied origin and adjuvant anti emetics 
1.2.2 COMPLICATIONS: 
Aspiration of vomit: 
Vomiting can be dangerous if the gastric content gets into the respiratory tract. 
Under normal circumstances the gag reflex and coughing prevent this from occurring; 
however these protective reflexes are compromised in persons under the influences of 
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certain substances such as alcohol or anesthesia. The individual may choke and 
asphyxiate or suffer an aspiration pneumonia. 
Dehydration and electrolyte imbalance: 
Prolonged and excessive vomiting depletes the body of water (dehydration), 
and may alter the electrolyte status. Gastric vomiting leads to the loss of acid 
(protons) and chlorine directly. Combined with the resulting alkaline tide, this leads to 
hypochloremic metabolic alkalosis (low chloride levels together with high HCO3 and 
CO2 and increased blood p
H
) and often hypokalemia (potassium depletion). The 
hypokalemia is an indirect result of the kidney compensating for the loss of acid. With 
the loss of intake of food the individual may eventually become cachectic. A less 
frequent occurrence results from a vomiting of intestinal contents, including bile acids 
and HCO3
- 
, which can lead to metabolic acidosis. 
Mallory-Weiss tear: 
Repeated or profuse vomiting may cause erosions to the esophagus or small 
tears in the esophageal mucosa (Mallory-Weiss tear). This may become apparent if 
fresh red blood is mixed with vomit after several episodes. 
Dentistry: 
Recurrent vomiting, such as observed in bulimia nervosa, may lead to 
destruction of the tooth enamel due to the acidity of the vomit. Digestive enzymes can 
also have a negative effect on oral health, by degrading the tissue of the gums. 
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1.2.3 Pathophysiology: 
Receptors on the floor of the fourth ventricle of the brain represent a 
chemoreceptor trigger zone, known as the area postrema, stimulation of which can 
lead to vomiting. The area postrema is a circumventricular organ and as such lies 
outside the blood-brain barrier; it can therefore be stimulated by blood-borne drugs 
that can stimulate vomiting or inhibit it. 
There are various sources of input to the vomiting center: 
• The chemoreceptor trigger zone at the base of the fourth ventricle has 
numerous dopamine D2 receptors, serotonin 5-HT3 receptors, opioid receptors, 
acetylcholine receptors, and receptors for substance P. Stimulation of different 
receptors are involved in different pathways leading to emesis, in the final 
common pathway substance P appears involved.  
• The vestibular system, which sends information to the brain via cranial nerve 
VIII (vestibulocochlear nerve), plays a major role in motion sickness, and is 
rich in Muscarinic receptors and histamine H1 receptors. 
• The Cranial nerve X (vagus nerve) is activated when the pharynx is irritated, 
leading to a gag reflex. 
• The Vagal and enteric nervous system inputs transmit information regarding 
the state of the gastrointestinal system. Irritation of the GI mucosa by 
chemotherapy, radiation, distention, or acute infectious gastroenteritis 
activates the 5-HT3 receptors of these inputs. 
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• The CNS mediates vomiting that arises from psychiatric disorders and stress 
from higher brain centers.  
The vomiting act encompasses three types of outputs initiated by the 
chemoreceptor trigger zone: Motor, parasympathetic nervous system (PNS), and 
sympathetic nervous system (SNS). They are as follows: 
• Increased salivation to protect tooth enamel from stomach acids. (Excessive vomiting 
leads to dental erosion). This is part of the PNS output. 
• The body takes a deep breath to avoid aspirating vomit. 
• Retroperistalsis, starts from the middle of the small intestine and sweeps up digestive 
tract contents into the stomach, through the relaxed pyloric sphincter. 
• Intra thoracic pressure lowers (by inspiration against a closed glottis), coupled with 
an increase in abdominal pressure as the abdominal muscles contract, propels 
stomach contents into the esophagus as the lower esophageal sphincter relaxes. The 
stomach itself does not contract in the process of vomiting except for at the angular 
notch, nor is there any retroperistalsis in the esophagus. 
• Vomiting is ordinarily preceded by retching. 
• Vomiting also initiates an SNS response causing both sweating and increased heart 
rate. 
The neurotransmitters that regulate vomiting are poorly understood, but 
inhibitors of dopamine, histamine, and serotonin are all used to suppress vomiting, 
suggesting that these play a role in the initiation or maintenance of a vomiting cycle. 
Vasopressin and neurokinin may also participate. 
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1.2.4 Phases: 
The vomiting act has two phases. In the retching phase, the abdominal muscles 
undergo a few rounds of coordinated contractions together with the diaphragm and the 
muscles used in respiratory inspiration. For this reason, an individual may confuse 
this phase with an episode of violent hiccups. In this retching phase nothing has yet 
been expelled. In the next phase, also termed the expulsive phase, intense pressure is 
formed in the stomach brought about by enormous shifts in both the diaphragm and 
the abdomen. These shifts are, in essence, vigorous contractions of these muscles that 
last for extended periods of time - much longer than a normal period of muscular 
contraction. The pressure is then suddenly released when the upper esophageal 
sphincter relaxes resulting in the expulsion of gastric contents. For people not in the 
habit of exercising the abdominal muscles, they may be painful for the next few days. 
The relief of pressure and the release of endorphins into the bloodstream after the 
expulsion cause the vomiter to feel better. 
1.2.5 Drug treatment in emesis 
[11]
: 
Classes of antiemetic drugs:  
a. Muscarinic receptor antagonists:  
Good for prevention of motion sickness. 
•     scopolamine  
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b. H1 antihistamines:  
For motion sickness, most antihistamines have additional anticholinergic 
action. Typical side effects of H1 antihistamines include drowsiness and loss of 
coordination. The newer antihistamines which do not cross the blood-brain barrier 
would not be useful.  
• Dimenhydrinate   
• Several Clizines  
• Diphenhydramine   
• Promethazine 
• Hydroxyzine  
• Meclizine  
 Anti dopaminergic drugs: 
 Most of these drugs are also used as antipsychotic agents. They have anti 
Muscarinic action.  
• Chlorpromazine 
• Droperidol (Inapsine) 
• Prochlorperazine 
• Metoclopramide  
• Fluphenazine 
• Domperidone  
• Haloperidol  
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• Droperidol has a "black box" warning and for this reason should not be lightly 
used for control of emesis. 
 Benzodiazepines:  
Good for anticipatory nausea and vomiting before cancer therapy. Also useful 
for vestibular disorders.  
• Diazepam  
• Lorazepam  
Corticosteroids:  
Mechanism of action not clear. May be related to the inhibition of arachidonic 
acid release. Dexamethasone is reportedly as effective as ondansetron for prevention 
of PONV  
• Dexamethasone  
• Methylprednisolone  
 Cannabinoids:  
Acts on higher centers in the cortex.  
Dronabinol (Rarely used until all else has failed).  
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5-HT3 receptor antagonists:  
This class of drugs is the most effective treatment available for prevention of 
severe vomiting due to cancer chemotherapy and cause little toxicity; about 85% of 
patients attain complete control of emesis and nausea. Usually given in combination 
with dexamethasone. Also widely used for PONV, but less effective. Although animal 
studies suggest it should not work for vestibular problems, empirically it is also often 
effective in this context.  
• Ondansetron  
• Tropisetron 
• Granisetron  
• Dolasetron  
 Miscellaneous:  
• Benzquinamide 
• Diphenidol  -- little used because of side effects (hallucinations)  
• Trimethobenzamide  
• Verapamil. 
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2. LITERATURE REVIEW 
Noha adel nafee et al. (2003) Mucoadhesive patches for delivery of 
cetylpyridinium chloride (CPC) were prepared using polyvinyl alcohol (PVA), 
hydroxyethylcellulose (HEC) and chitosan. Swelling and bioadhesive characteristics 
were determined for both plain and medicated patches. The results showed a 
remarkable increase in radial swelling (SD) after addition of the water-soluble drug 
(CPC) to the plain formulae. A decrease in the residence time was observed for PVA 
and chitosan-containing formulae. Higher drug release was obtained from PVA 
patches compared to HEC ones, while both are non-ionic polymers. A considerable 
drop in release was observed for chitosan formulae after the addition of water-soluble 
additives, polyvinyl pyrolidine (PVP) and gelatin. Ageing was done on PVA 
formulae; the results showed there was no influence on the chemical stability of CPC, 
as reflected from the drug content data. Physical characteristics of the studied patches 
showed an increase in the residence time with storage accompanied with a decrease in 
drug release. This may be due to changes in the crystal habit of the drug as well as to 
slight agglomeration of the polymer particles. 
 
Angela Abruzzo et al. (2004) The aim of this work was to develop 
chitosan/gelatin mucoadhesive films for buccal delivery of propranolol hydrochloride, 
an antihypertensive agent. Buccal route ensures systemic availability, avoiding a 
possible drug degradation in the gastrointestinal tract and first-pass metabolism. 
Chitosan/gelatin complexes based films, obtained in different chitosan/gelatin weight 
ratio, and were prepared by a casting-solvent evaporation technique. Films were 
characterized by FT-IR, DSC, TGA, and in terms of thickness, morphology, drug 
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content uniformity and water-uptake properties. Furthermore, drug release and 
permeation, in vitro and in vivo mucoadhesion studies were performed[3]. Results 
confirmed the interaction between chitosan and gelatin. Films with a great amount of 
gelatin showed high water-uptake ability and provided a limited drug release and 
permeation, due to possible interactions between drug and gelatin. Films presented 
good in vitro and in vivo mucoadhesion properties and no irritative effect. 
 
Subash Pillai et al. (2005) An attempt was made to formulate Buccal patches 
of Isoxsuprine hydrochloride, a potent and long acting vasodilator and uterine 
suppressant , by using Hydroxyl propyl methyl cellulose(HPMC), Polyvinyl 
pyrolidone K-30 (PVP K-30) and Hydroxyl ethyl cellulose (HEC). Twelve batches of 
buccal patches were prepared by solvent casting technique in which the best 
formulation was found out. The polymers HPMC, HEC, and PVP K-30 were 
incorporated with Isoxsuprine hydrochloride in various proportions, out of which the 
best formulation on the ratio (HPMC: HEC: PVPK-30-2:2:1) with the drug was 
determined. Prepared buccal patches were spherical, uniform in shape and white in 
colour. The obtained buccal films were evaluated for physicochemical characteristics, 
In-vitro release profile, Ex-vivo diffusion study in fresh goat cheek pouch membrane 
and In-vivo evaluation in rabbits. Higuchi’s plot studies revealed that the predominant 
mechanism of drug release was diffusion. 
 
Shiva S Krishna et al. (2006) Extending the residence time of a dosage form 
at a particular site and controlling the release of drug from the dosage form are useful 
especially for achieving controlled plasma level of the drug as well as improving 
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bioavailability. The objective of this study was to extend the GI residence time of the 
dosage form and control the release of rosiglitazone using mucoadhesive tablet to 
achieve controlled plasma level of the drug which is especially useful after 8 to 12 
weeks of monotherapy using conventional dosage forms when dose is doubled and 
plasma level also doubles. Direct compression method using simplex lattice design, 
followed by optimization of the evaluation parameters was employed to get final 
optimized formulation. The optimized formulation showed a muccoadhesive strength 
>40 gm-f, and a mucoadhesion time >12 hours with release profile closer to the target 
release profile and followed Non-Fickian diffusion mediated release of rosiglitazone 
maleate. 
 
Vishnu M. Patel et al. (2006) Mucoadhesive buccal patches containing 
propranolol hydrochloride were prepared using the solvent casting method. Chitosan 
was used as bioadhesive polymer and different ratios of chitosan to PVP K-30 were 
used. The patches were evaluated for their physical characteristics like mass variation, 
drug content uniformity, folding endurance, ex vivo mucoadhesion strength, ex vivo 
mucoadhesion time, surface pH, in vitro drug release, and in vitro buccal permeation 
study. Patches exhibited controlled release for a period of 7 h. The mechanism of drug 
release was found to be non-Fickian diffusion and followed the first-order kinetics. 
Incorporation of PVP K-30 generally enhanced the release rate. Swelling index was 
proportional to the concentration of PVP K-30. Optimized patches (F4) showed 
satisfactory bioadhesive strength of 9.6 ± 2.0 g, and ex vivo mucoadhesion time of 
272 minutes. The surface pH of all patches was between 5.7 and 6.3 and hence 
patches should not cause irritation in the buccal cavity. Patches containing 10 mg of 
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drug had higher bioadhesive strength with sustained drug release as compared to 
patches containing 20 mg of drug. Good correlation was observed between the in vitro 
drug release and in vitro drug permeation with a correlation coefficient of 0.9364. 
Stability study of optimized patches was done in human saliva and it was found that 
both drug and buccal patches were stable. 
 
Mona Semalty et al. (2007) For improving bioavailability in controlled 
release fashion and to circumvent the hepatic first pass effect of glipizide 
mucoadhesive buccal films of glipizide were prepared by solvent casting technique. 
Buccal films were prepared using hydroxy propylmethylcellulose, sodium 
carboxymethylcellulose, carbopol- 934P and Eudragit RL-100. Films were evaluated 
for their weight, thickness, surface pH, swelling index, in vitro residence time, folding 
endurance, in vitro release, ex vivo permeation studies and drug content uniformity. 
The films exhibited controlled release over more than 6 h. From the study it was 
concluded that the films containing 5 mg glipizide in 4.9 % w/v hydroxy 
propylmethylcellulose and 1.5 % w/v sodium carboxymethylcellulose exhibited 
satisfactory swelling, an optimum residence time and promising drug release thus 
proved to be potential candidate for the development of buccal films for therapeutic 
use. 
 
S. Singh et al. (2008) buccal bioadhesive films, releasing topical drugs in the 
oral cavity at a slow and predetermined rate, provide distinct advantages over 
traditional dosage forms. The aim of present study was to prepare and evaluate buccal 
bioadhesive films of clotrimazole for oral candidiasis. The film was designed to 
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release the drug at a concentration above the minimum inhibitory concentration for a 
prolonged period of time so as to reduce the frequency of administration of the 
available conventional dosage forms. The different proportions of sodium 
carboxymethylcellulose and Carbopol 974P (CP 974P) were used for the preparation 
of films. Carbopol was used to incorporate the desired bioadhesiveness in the films. 
The films were prepared by solvent casting method and evaluated for bioadhesion, in 
vitro drug release and effectiveness against Candida albicans. In vitro drug release 
from the film was determined using a modified Franz diffusion cell while 
bioadhesiveness was evaluated with a modified two-arm balance using rabbit 
intestinal mucosa as a model tissue. Films containing 5% CP 974P of the total 
polymer were found to be the best with moderate swelling along with favorable 
bioadhesion force, residence time and in vitro drug release.  
 
Claudia Juliano et al.  (2008) The aim of this work was to investigate the 
suitability of some polymeric films as buccal systems for the delivery of the antiseptic 
drug Chlorhexidine diacetate, considered as a valid adjunct in the treatment of oral 
candidiasis. Six different film formulations, mono- or double-layered, containing 5 or 
10 mg of Chlorhexidine diacetate, respectively, and alginate and/or 
hydroxypropylmethylcellulose and/or chitosan as excipients, were prepared by a 
casting-solvent evaporation technique and characterized in terms of drug content, 
morphology (scanning electron microscopy), drug release behavior, and swelling 
properties. Moreover, the in vivo concentrations of Chlorhexidine diacetate in saliva 
were evaluated after application of a selected formulation on the oral mucosa of 
healthy volunteers. The behavior of a selected formulation, chosen on the basis of its 
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in vitro release results, was preliminarily investigated in vivo after application in the 
oral cavity of healthy volunteers. The films were well tolerated and the salivary 
Chlorhexidine concentrations were maintained above the minimum inhibitory 
concentration for Candida albicans for almost 3 h. These preliminary results indicate 
that polymeric films can represent a valid vehicle for buccal delivery of antifungal/ 
antimicrobial drugs. 
 
J. Sahni et al. (2008.) A buccoadhesive drug delivery system of Insulin was 
prepared by solvent casting technique and characterized in vitro by surface pH, 
bioadhesive strength, drug release and skin permeation studies. Sodium 
carboxymethylcellulose-DVP was chosen as the controlled release matrix polymer. 
The optimized formulation J4 contained Sodium carboxy methyl cellulose-DVP 2% 
(w/v), insulin (50 IU/film), propylene glycol (0.25 ml) and Isopropyl alcohol: water 
(1:4) as solvent system. In vitro release studies were carried out at 37 ± 2° using 
phosphate buffer pH 6.6, in a modified dissolution apparatus fabricated for the 
purpose. Cumulative amount of drug released from the optimized formulation J4 was 
91.64% in 6 hours. In vitro permeation studies were carried out on J4 at 37 ± 2° using 
Franz diffusion cell. Cumulative amount of drug permeated from J4 was 6.63% in 6 
hours. The results suggested that sodium deoxycholate 5% (w/v) was the best 
permeation enhancer among those evaluated. It enhanced the permeation of insulin 
from 6.63% to 10.38% over a period of 6 hours. The optimized patches were also 
satisfactory in terms of surface pH and bioadhesive strength. It can also be easily 
concluded that the system is a success as compared to the conventional formulations 
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with respect to invasiveness, requirement of trained persons for administration and 
most importantly, the first pass metabolism. 
 
Mona Semalty et al.(2008) Mucoadhesive buccal films of glipizide were 
prepared by solvent casting technique using hydroxypropylmethylcellulose, sodium 
carboxymethylcellulose, carbopol-934P and Eudragit RL-100. Prepared films were 
evaluated for weight, thickness, surface pH, swelling index, in vitro residence time, 
folding endurance, in vitro release, permeation studies and drug content uniformity. 
The films exhibited controlled release over more than 6 h. From the study it was 
concluded that the films containing 5 mg glipizide in 4.9% w/v 
hydroxypropylmethylcellulose and 1.5% w/v sodium carboxymethylcellulose 
exhibited satisfactory swelling, an optimum residence time and promising drug 
release. The formulation was found to be suitable candidate for the development of 
buccal films for therapeutic use. 
 
M. Nappinnai et al. (2008.) A mucoadhesive drug delivery system for 
systemic delivery of nitrendipine, a calcium channel blocker through buccal route was 
formulated. Mucoadhesive polymers like hydroxypropylmethylcellulose K-100, 
hydroxypropylcellulose, sodium carboxymethylcellulose, sodium alginate, polyvinyl 
alcohol, polyvinyl pyrolidine K-30 and carbopol-934P were used for film fabrication. 
The films were evaluated for their weight, thickness, percentage moisture absorbed 
and lost, surface pH, folding endurance, drug content uniformity, In vitro residence 
time, In vitro release and ex vivo permeation. Based on the evaluation of these results, 
it was concluded that buccal films made of hydroxypropylcellulose and sodium 
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carboxymethylcellulose (5±2% w/v; F-4), which showed moderate drug release (50% 
w/w at the end of 2 h) and satisfactory film characteristics could be selected as the 
best among the formulations studied. 
 
B. K. Satishbabu et al. (2008.) This paper describes the preparation of new 
bilayered device comprising a drug containing mucoadhesive layer and a drug free 
backing layer. Bilaminated films were produced by a casting/ solvent evaporation 
technique. The mucoadhesive layer was composed of mixture of drug and sodium 
alginate with or without carbopol 934 P, and backing layer was made of ethyl 
cellulose. The double layer structure design was expected to provide drug delivery in 
a unidirectional fashion to the mucosa and avoid loss of drug due to wash out with 
saliva. The fabricated films were subjected to in vitro drug release, in vitro 
permeation through porcine buccal mucosa. The bilayered films were also evaluated 
for mucoadhesive strength, mucoadhesive time, folding endurance, hydration studies 
and tensile strength. 
 
Soad A. Yehia et al. (2009) Fluconazole mucoadhesive buccal films were 
prepared using film forming polymers namely; hydroxypropylmethylcellulose 
(HPMC), hydroxyethyl cellulose (HEC), chitosan, Eudragit and sodium alginate 
(SALG) either alone or in combination with bioadhesive polymers. The bioadhesive 
polymers studied were sodium carboxymethyl cellulose (SCMC), Carbopol 974P, and 
polycarbophil (AA-A). The prepared films were characterized by means of film 
thickness, surface pH, swelling capacity, in vitro adhesion, in vivo residence time, in 
vitro drug release and in vivo drug release to determine the amount of drug release 
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from selected film formulae using microbiological assay and HPLC. Optimum release 
behavior, convenient bioadhesion, acceptable elasticity were exhibited by film 
containing 2% HPMC and 1% SCMC (fresh or stored for 6 months). Determination of 
the amount of drug released in saliva after application of the selected fluconazole 
films confirmed the ability of the film to deliver the drug over a period of 
approximately 300 minutes and to reduce side effects and possibility of drug 
interaction encountered during systemic therapy of fluconazole, which would be 
beneficial in the case of oral candidiasis. 
Amit Khairnar et al. (2009) Mucoadhesive buccal patch of Aceclofenac were 
prepared using polymer like Gelatin, Poly Sodium CMC and Poly Vinyl Alcohol. 
Eight formulations were prepared with varying the concentration of Poly Sodium 
CMC and evaluated for various parameters like weight variation, patch thickness, 
volume entrapment efficiency %, and measurement of % elongation at break, folding 
endurance, in vitro mucoadhesive time, in vitro release and stability study. The 
formulations showed a sustained release. The F5 formulation containing Aceclofenac 
6%, Gelatin 4.5%, Poly Sodium CMC 5.5%, Propylene Glycol 5%, Poly vinyl 
Alcohol 2.5% and Distilled Water up to 100%, showed a release of 88.4% after 8 
hours. The Aceclofenac stability studies were performed at 40 ± 2 0C / 75 ± 5% RH. 
Among the eight formulation, F5 formulation showed maximum desired properties 
release. 
 
M. Alagusundaram et al. (2009) Bioadhesive formulations have a wide scope 
of application for both systemic and local effects of drugs. The mucosa is relatively 
permeable, well supplied with both vascular and lymphatic drainage. The oral 
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transmucosal drug delivery bypasses liver and avoids presystemic elimination in the 
gastro intestinal tract and liver. The present investigation highlights the formulation 
and evaluation of mucoadhesive buccal films of ranitidine. The mucoadhesive buccal 
films of ranitidine were prepared by solvent casting technique using polymers like 
hydroxy propyl methyl cellulose-15 cps and poly vinyl pyrrolidone. The formulated 
films were evaluated for their physiochemical parameters like surface pH, percentage 
moisture absorption, percentage moisture loss, swelling percentage, water vapour 
transmission rate, thickness, weight of the films, folding endurance and drug content. 
In vitro release studies were performed with pH 6.8 phosphate buffer solution. Good 
results were obtained both in physico chemical characteristics and in vitro studies. 
The films exhibited controlled release more than 10 h. The in vitro release data were 
fit to different equations and kinetic models to explain release profiles. The 
correlation coefficient value (r) indicates the kinetic of drug release was zero order. 
The formulation was found to be right and suitable candidate for the formulation of 
ranitidine buccal film for therapeutic use. 
 
Y. Vamshi Vishnu et al. (2007) A buccal patch for systemic administration of 
carvedilol in the oral cavity has been developed using two different mucoadhesive 
polymers. The formulations were tested for in vitro drug permeation studies, buccal 
absorption test, in vitro release studies, moisture absorption studies and in vitro 
bioadhesion studies. The physicochemical interactions between carvedilol and 
polymers were investigated by Fourier transform infrared (FTIR) Spectroscopy. 
According to FTIR the drug did not show any evidence of an interaction with the 
polymers used and was present in an unchanged state. XRD studies reveal that the 
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drug is in crystalline state in the polymer matrix. The results indicate that suitable 
bioadhesive buccal patches with desired permeability could be prepared. 
Bioavailability studies in healthy pigs reveal that carvedilol has got good buccal 
absorption. The bioavailability of carvedilol from buccal patches has increased 2.29 
folds when compared to that of oral solution. The formulation AC5 (HPMC E 15) 
shows 84.85 + 0.089% release and 38.69 + 6.61% permeated through porcine buccal 
membrane in 4 hr. The basic pharmacokinetic parameters like the Cmax, Tmax and 
AUCtotal were calculated and showed statistically significant difference (P<0.05) 
when given by buccal route compared to that of oral solution. 
 
Rajesh Singh Patel et al. (2009) Mucoadhesive patch releasing the drug in 
the oral cavity at predetermined rate may present distinct advantages over traditional 
dosage forms such as tablets, gels and solutions. The present study was concerned 
with the preparation and evaluation of mucoadhesive buccal patches for the controlled 
systemic delivery of Salbutamol sulphate to avoid first pass hepatic metabolism. The 
developed patches were evaluated for the physicochemical, mechanical and drug 
release characteristics. The patches showed desired mechanical and physicochemical 
properties to withstand environment of oral cavity. The in-vitro release study showed 
that patches could deliver drug to the oral mucosa for a period of 7 h. the patches 
exhibited adequate stability when tested under accelerated conditions. 
 
Vishnu M. Patel et al. (2009) Mucoadhesive buccal patches containing 
propranolol hydrochloride were prepared using solvent casting method was develop 
and evaluate for in-vitro performance using hydrophobic polymer eudragit L-100. In 
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preparation of patches hydrophilic polymers like carbopol-934 and PVP K-30 were 
incorporated to modify bioadhesive properties, and drug release rate. Patches were 
evaluated for surface pH, folding endurance, swelling index, ex-vivo mucoadhesive 
strength, in-vitro drug release and in-vitro buccal permeation. The prepared patches 
were smooth, elegant in appearance, uniform in thickness, weight, and drug content 
and showed no visible cracks and showing good folding endurance. Results indicates 
that the high amount of carbopol 934 and low amount of PVP K30 favor the ex-vivo 
mucoadhesive strength of the patches but low amount of carbopol 934 and high 
amount of PVP K30 favor the dissolution rate (t50, t80) and swelling index of the 
patches. It can be concluded from present study that mucoadhesive patches of 
eudragit could be a useful carrier in buccal drug delivery systems. 
Chandra Sekhar Kolli et al. (2009) The aim of this investigation was to 
develop and evaluate mucoadhesive buccal patches of prochlorperazine (PCPZ). 
Permeation of PCPZ was calculated in vitro using porcine buccal membrane. Buccal 
formulations were developed by solvent-casting technique using hydroxy 
propylmethyl cellulose (HPMC) as mucoadhesive polymer. The patches were 
evaluated for in vitro release, moisture absorption and mechanical properties. The 
optimized formulation, based on in vitro release and moisture absorption studies, was 
subjected for bioadhesion studies using porcine buccal membrane. In vitro flux of 
PCPZ was calculated to be 2.14 ± 0.01 g. h–1.cm–2 and buccal absorption was also 
demonstrated in vivo in human volunteers. In vitro drug release and moisture 
absorbed was governed by HPMC content. Increasing concentration of HPMC 
delayed the drug release. All formulations followed Zero order release kinetics 
whereas the release pattern was non-Fickian. The mechanical properties, tensile 
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strength (10.28 ± 2.27 kg mm–2 for formulation P3) and elongation at break reveal 
that the formulations were found to be strong but not brittle. The peak detachment 
force and work of adhesion for formulation P3 were 0.68 ± 0.15 N and 0.14 ± 0.08 
mJ, respectively. The results indicate that suitable bioadhesive buccal patches of 
PCPZ with desired permeability and suitable mechanical properties could be 
prepared. 
 
R.S. Hirlekar et al. (2009) Carvedilol is an antihypertensive drug used in the 
treatment of congestive heart failure, cardiac arrhythmias and angina pectoris. It 
exhibits poor bioavailability of 25-30% which is attributed to its poor solubility and 
high first pass metabolism. The present work was aimed at overcoming these two 
limitations. Drug-Methyl--cyclodextrin complex was prepared by kneading method 
and characterized by Fourier Transformation Infrared spectroscopy, Differential 
Scanning Calorimetry and powder X-Ray Diffractometry studies. Dissolution rate of 
complex was compared with plain drug and physical mixture. The complex was 
incorporated into buccal tablet. The buccal tablets were evaluated for drug release, 
mucoadhesive strength and ex-vivo permeability. Characterization of binary system 
revealed the formation of inclusion complex of drug with Methyl--cyclodextrin. The 
complex showed complete release as compared to 32.8% and 42.7% from plain drug 
and physical mixture respectively in 60min. Tablets containing complex showed 
complete release at the end of 180min compared to 40.23% from tablets containing 
plain drug. The buccal tablets containing complex had good mucoadhesive strength. 
The amount of drug permeated from these tablets across the porcine buccal mucosa at 
the end of 5h was 6.2mg as compared to 2.51mg from tablets containing plain drug. 
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Thus it can be concluded that buccal tablet containing complexed CAR would have 
improvement in bioavailability.  
 
Subhash V. Deshmane et al. (2009) The buccal region of the oral cavity is an 
attractive target for administration of the drug of choice. Sustained release 
formulations have been developed and are gaining in popularity and medical 
acceptance. To increase bioavailability and prevent first pass metabolism of drug, 
verapamil hydrochloride was embedded in sustained released buccal patch over 
period of 6 hour. The objective of present work was to characterize the effect of 
chitosan with PVP K-30 on water soluble drug by preparing mucoadhesive buccal 
patch. Each formulated batch was subjected to various evaluation parameters. The 
swelling percentage was found to be function of solubility of drug and PVP K-30. The 
mucoadhesive strength, vapour transmission and in-vitro released of water soluble 
drug through water insoluble chitosan base matrix were found satisfactorily. The 
physical appearance of buccal patch was examined by scanning electron microscopy. 
The released kinetic model best to fit for the optimized batch was Hixson Crowell, 
indicating that the drug release from systems in which there is a change in the surface 
area and the diameter of particles present in dosage form. 
 
Surya N. Ratha Adhikari et al.(2010) Buccal patches for the delivery of 
atenolol using sodium alginate with various hydrophilic polymers like Carbopol 934 
P, sodium carboxymethyl cellulose, and hydroxypropylmethylcellulose in various 
proportions and combinations were fabricated by solvent casting technique. Various 
physic mechanical parameters like weight variation, thickness, folding endurance, 
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drug content, moisture content, moisture absorption, and various ex vivo 
mucoadhesion parameters like mucoadhesive strength, force of adhesion, and bond 
strength were evaluated. An in vitro drug release study was designed, and it was 
carried out using commercial semi permeable membrane. All these fabricated patches 
were sustained for 24 h and obeyed first-order release kinetics. Ex vivo drug 
permeation study was also performed using porcine buccal mucosa and various drug 
permeation parameters like flux and lag time were determined. 
 
A Semalty et al. (2010.) Enalapril maleate is used in the treatment of 
hypertension and angina pectoris. It shows low bioavailability due to high hepatic first 
pass metabolism. Hence the present work was undertaken to formulate mucoadhesive 
buccal films of Enalapril maleate with an objective to improve therapeutic efficacy, 
patient compliance and the bioavailability. In the present study ten formulations of 
mucoadhesive drug delivery system of Enalapril maleate were prepared as buccal 
films, by solvent casting technique. Sodium carboxymethylcellulose, hydroxyl propyl 
methyl cellulose, hydroxyethylcellulose and polyvinyl pyrolidine K-90 were used as 
mucoadhesive polymers. Prepared films were evaluated for their weight, thickness, 
surface pH, swelling index, drug content uniformity, in vitro residence time, folding 
endurance in vitro release and permeation studies. Films exhibited controlled release 
over more than 10 h in permeation studies. It was concluded that the films containing 
20 mg of Enalapril maleate in sodium carboxymethylcellulose 2% w/v and 
hydroxyethylcellulose 2% w/v (formulation F5), showed good swelling, a convenient 
residence time and promising controlled drug release, thus can be selected for the 
development of buccal film for effective therapeutic uses. 
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Rahamatullah Shaikh et al. (2010) Mucoadhesion is commonly defined as 
the adhesion between two materials, at least one of which is a mucosal surface. Over 
the past few decades, mucosal drug delivery has received a great deal of attention. 
Mucoadhesive dosage forms may be designed to enable prolonged retention at the site 
of application, providing a controlled rate of drug release for improved therapeutic 
outcome. Application of dosage forms to mucosal surfaces may be of benefit to drug 
molecules not amenable to the oral route, such as those that undergo acid degradation 
or extensive first-pass metabolism. The mucoadhesive ability of a dosage form is 
dependent upon a variety of factors, including the nature of the mucosal tissue and the 
physicochemical properties of the polymeric formulation. This review article aims to 
provide an overview of the various aspects of mucoadhesion, mucoadhesive materials, 
factors affecting mucoadhesion, evaluating methods, and finally various 
mucoadhesive drug delivery systems (buccal, nasal, ocular, gastro, vaginal, and 
rectal). 
Rana M. Obaidat et al. (2010.) The specific aim of this work was to prepare 
mucoadhesive patches containing tetracycline hydrochloride and carvacrol in an 
attempt to develop a novel oral drug delivery system for the treatment of mouth 
infections. The bilayered patches were prepared using ethyl cellulose as a backing 
layer and carbopol 934 as a matrix mucoadhesive layer. Patches were prepared with 
different loading amounts of tetracycline hydrochloride and carvacrol. The 
antimicrobial activity was assessed for the prepared patches using the disc-diffusion 
method against the yeast Candida albicans and five bacterial strains, including 
Pseudomonas aeruginosa, Escherichia coli, Bacillus cereus, Staphylococcus aureus, 
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and Bacillus bronchispti. In this work, we highlighted the possibility of occurrence of 
a synergistic action between carvacrol and tetracycline. The best formulation was 
selected based on microbiological tests, drug release, ex-vivo mucoadhesive 
performance, and swelling index. Physical characteristics of the selected formulations 
were determined. These included pH, patch thickness, weight uniformity, content 
uniformity, folding endurance, and patch stability. 
 
Sathish Dharani et al.  (2010) The goal of the present investigation was to 
design and evaluate mucoadhesive buccal patches of Ondansetron Hydrochloride 
(OND) which is used for nausea and vomiting associated with cancer chemotherapy 
and radiotherapy. Permeation of OND was calculated ex vivo using porcine buccal 
membrane. Buccal films were developed by solvent-casting technique using Hydroxy 
Propyl Methyl Cellulose(HPMC E15) as mucoadhesive polymer. The patches were 
evaluated for weight variation, thickness variation, surface pH, moisture absorption, 
in vitro residence time, mechanical properties, in vitro release, ex vivo permeation 
studies and drug content uniformity. The formulation F3 was found to give the better 
results and obeys first order kinetics. 
 
Rohit Chaudhary et al. (2010) The goal of present investigation was to 
design and evaluate mucoadhesive bilayered buccal devices comprising a drug 
containing mucoadhesive layer and a drug free backing membrane. Bilaminatd 
patches composed of mixture of drug (Methotrexate) and sodium alginate alone or in 
combination with sodium carboxy methylcellulose ,Polyvinylpyrrolidine and carbopol 
934 and backing membrane (Ethyl cellulose).The patches were fabricated by solvent 
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casting technique and were evaluated for In-Vitro and Ex-Vivo drug release. The 
patches were evaluated for film weight uniformity, thickness, swelling index, surface 
pH, mucoadhesive strength and mucoadhesive time and folding endurance. A 
combination of sodium alginate with carbopol-934 and glycerol as plasticizer gives 
promising results. The optimized patch exhibit an in vitro release of 82% through 
cellophane membrane and 70.78 % through buccal mucosa with satisfactory 
mucoadhesive strength and mucoadhesive time. 
 
Marina Koland et al. (2010) Buccal delivery is considered to be an important 
alternative to the peroral route for the systemic administration of drugs. Losartan 
potassium is an angiotensin II receptor antagonist with an oral bioavailability of only 
33% due to extensive first pass metabolism. Mucoadhesive buccal films of losartan 
potassium were prepared using hydroxypropyl methyl cellulose (HPMC) and 
retardant polymers ethyl cellulose (EC) or eudragit RS 100. Thermal analysis by DSC 
of formulations show no interaction between drug and polymers. Ex vivo permeation 
studies of losartan potassium solution through porcine buccal mucosa showed 90.2 % 
absorption at the end of 2 hours. The films were subjected to physical investigations 
such as uniformity of thickness, weight, drug content, folding endurance, tensile 
strength, elongation at break, surface pH and mucoadhesive strength. Films were 
flexible and those formulated from EC were smooth whereas those prepared from 
Eudragit were slightly rough in texture. The mucoadhesive force, swelling index, 
tensile strength and percentage elongation at break was higher for those formulations 
containing higher percentage of HPMC. In vitro drug release studies reveal that all 
films exhibited sustained release in the range of 90.10 to 97.40 % for a period of 6 
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hours. The data was subjected to kinetic analysis which indicated non Fickian 
diffusion for all formulations except E2. Ex vivo permeation studies through porcine 
buccal mucosa indicate that films containing higher percentage of the mucoadhesive 
polymer HPMC showed slower permeation of the drug for 6-7 hours. 
 
Vijendra Suryawanshi et al. (2010) Buccoadhesive tablets have long been 
employed to improve the bioavailability of drugs undergoing significant first pass 
hepatic metabolism. Dimenhydrinate is an anti-emetic drug. It was under goes 
extensive first pass metabolism resulting in an oral bioavailability of 46 % and it 
shows variable absorption from GIT. Buccal route offers several advantages such as 
rapid absorption, high plasma concentration level and ease of administration and 
termination of therapy. The present investigation concerns the development of 
Buccoadhesive tablets of Dimenhydrinate which were designed to prolong the buccal 
residence time after oral administration. Buccal tablets of Dimenhydrinate were 
formulated using four mucoadhesive polymers namely, Carbopol 934 P, HPMC K4M, 
HPMC K15M and Sodium carboxymethylcellulose carried out studies for weight 
variation, thickness, hardness, content uniformity, swelling index, Bioadhesive force 
and in vitro drug release. Formulation of F5 were formulated by using polymers 
Carbopol 934 P and Sodium carboxymethylcellulose provided controlled release of 
Dimenhydrinate over period of 8 hrs. The cumulative % of drug release of 
formulation F5 were 96.67. In-vitro releases of F1 to F9 were found to be diffusion 
controlled and followed zero order kinetics. The stability studies showed that there 
was no significant change in adhesive strength, in-vitro release when stored at room 
temperature, 40oC, 2-8 
o
C for a period of 30 days. Formulation of F5 which were 
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formulated by using polymers Carbopol 934 P and Sodium carboxymethylcellulose 
were established to be the optimum formulation with optimum bioadhesive force, 
swelling index & desired in-vitro drug release. Further investigations are needed to 
confirm the in-vivo efficiency, long term stability studies are needed to stabilize the 
controlled released (F5) formulations. 
D. Sandeep kumar et al. (2010) The goal of the present investigation was to 
design and evaluate mucoadhesive bi-layered buccal devices comprising a drug 
containing mucoadhesive layer and a drug free backing membrane. Bilaminated films 
composed of mixture of drug (lornoxicam) and chitosan, with hydroxyl-propyl 
methylcellulose (15 cps) and backing layer (ethyl cellulose). Films were fabricated by 
solvent casting technique and were evaluated for thickness, drug content uniformity, 
bio-adhesion strength, percent, swelling index, folding endurance and in vitro drug 
release. A combination of chitosan and hydroxylpropyl methylcellulose (1:1) using 
propylene glycol (50% by weight of polymer) as plasticizer gave promising results. 
The optimized film exhibited an In vitro drug release of approximately 90% in 5 hrs 
along with satisfactory bio-adhesive strength. Promising film was tested for drug 
excipient interaction (FTIR). FTIR spectra indicated that there are no drug-excipient 
interactions. 
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3.1 DRUG PROFILE 
DIMENHYDRINATE 
Generic name:  
Dimenhydrinatum, Diphenhydrinate, Dramamine, Gravol and Vertirosan. 
Description: 
Dimenhydrinate is an over-the-counter drug used to prevent motion sickness. 
It is closely related to diphenhydramine HCl, or Benadryl. It is primarily a H1-
antagonist, but also possesses an antimuscarinic effect. 
Structure: 
 
Molecular formula:  
C24H28ClN5O3 
Chemical name: 
8-chloro-1,3-dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-7-ide;[2-
(diphenylmethoxy) ethyl]dimethylazanium 
Melting point: 
102 °C to 106 °C. 
Chapter-3                                                                                           Drug and excipient profile 
	
Dept. of Pharmaceutics, The Erode College of Pharmacy & Research Institute  


Molecular weight:  
469.964 
Solubility: 
Water solubility 3000 mg/L, Insoluble in Acids and Alkalines. 
Therapeutic class:  
Used for treating vertigo, motion sickness, and nausea associated with 
pregnancy. 
Storage: 
Store in an airtight container, protected from light. 
Pharmacokinetic parameters 
Absorption: 
Well absorbed after oral administration. 
Distribution: 
Probably widely distributed into body tissues; crosses the placenta; small 
amounts in breast milk but no information about crossing blood brain barrier. 
Metabolism: 
Hepatic (cytochrome P-450 system) 
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Elimination: 
Renal route. 
Duration of action: 
 4-6 hours 
Mechanism of action/effect:  
The mechanism by which some antihistamines exert their antiemetic, anti–
motion sickness, and antivertigo effects is not precisely known but may be related to 
their central anticholinergic actions. They diminish vestibular stimulation and depress 
labyrinthine function. An action on the medullary chemoreceptive trigger zone may 
also be involved in the antiemetic effect. Dimenhydrinate is a competitive antagonist 
at the histamine H1 receptor, which is widely distributed in the human brain. 
Dimenhydrinate's anti-emetic effect is probably due to H1 antagonism in the 
vestibular system in the brain. 
Precautions to consider: 
Symptoms of overdose include delirium, hallucinations, and excitement. 
Patients may be violent and confused. 
Side/adverse effects: 
 Drowsiness, confusion, restlessness, headache, dizziness, blurring of vision 
Indications: 
Treatment of nausea and vomiting caused by drug or motion sickness. 
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3.2 EXCIPIENT PROFILE 
3.2.1 HYDROXY PROPYL METHYL CELLULOSE E15 
Non-proprietary names: 
 Hypromellose, Hydroxyl propyl methyl cellulose2208, 2906. 
Synonyms: 
Methyl hydroxyl propyl cellulose, propylene glycol ether of methyl cellulose, 
methyl cellulose propylene glycol ether. 
Description: 
 An odorless, tasteless, white or creamy white colored fibrous or granular 
powder. 
Structural formula: 
 
Chemical name: 
 Cellulose, 2-hydroxypropylmethyl ether, cellulose hydroxypropylmethyl ether 
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Molecular weight:  
Approximately 86,000 
Functional category: 
 Coating agent, film former, tablet binder, stabilizing agent, suspending agent, 
viscosity increasing agent, and emulsion stabilizer. 
Density: 
 Bulk Density -0.341 g/cm
3 
 
Tapped Density -0.557 g/cm
3
 
 True Density -1.326 g/cm
3
 
Solubility: 
 Soluble in cold water forming viscous colloidal solution, insoluble in 
chloroform, alcohol and ether, but soluble in methanol and methylene chloride. 
Viscosity: 
15 mPas 
Stability and storage conditions: 
 Very stable in dry conditions. Solutions are stable at P
H
 3.0-11.0.  
 Store in a tight container, in a cool place. 
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Incompatibilities: 
 Extreme P
H
 conditions, oxidizing materials. 
Safety: 
 Human and animal feeding studies have shown HPMC to be safe. 
3.2.2 HYDROXY ETHYL CELLULOSE 
Synonyms: 
 Hydroxyethyl ether, Hydroxyethylcellulose, 2-hydroxyethyl cellulose 
Description: 
Hydroxy ethyl cellulose is a gelling and thickening agent derived from 
cellulose. It is widely used in cosmetics, cleaning solutions, and other household 
products. Hydroxyethyl cellulose and methyl cellulose are frequently used with 
hydrophobic drugs in capsule formulations, to improve the drugs' dissolution in the 
gastrointestinal fluids. This process is known as "Hydrophilization" 
Structural formula: 
 
Chemical name: 
2-hydroxyethyl ether 
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Melting point: 
Softens at 135–140
0
C, decomposes at about 205
0
C. 
Functional category: 
HEC is mainly used as adhesive protective gelatin, thicker agent and 
stabilizing agent as well as additives to make emulsion, frozen gelatin, lotion, eye 
clear agent, suppository and tablets. HEC is also used for hydrophilic colloid, 
framework, material, ready-made framework controlled release agent, and stabilizing 
agent in foodstuff. 
Apparent density: 
  0.35–0.61 g/cm
3
 
Solubility: 
It can dissolve in other cool or hot water. Normally, it does not dissolve in 
organic solvents. Viscosity change is small when pH value is within 2 to 12 but 
decrease when p
H
 value is low than the range. 
Viscosity: 
5 - 100,000mPa.s 
Stability and storage conditions: 
Keep dry in ventilated places and keep away from sunshine during 
transportation 
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Incompatibilities: 
Hydroxy ethyl cellulose is insoluble in most organic solvents. It is 
incompatible with zein and partially compatible with the following water-soluble 
compounds: casein, gelatin, methylcellulose, polyvinyl alcohol and starch. 
Safety: 
Hydroxy ethyl cellulose is primarily used in ophthalmic and topical 
pharmaceutical formulations. It is generally regarded as an essentially nontoxic and 
nonirritant material. 
 
3.2.3 POLY VINYL PYRROLIDINE 
Synonyms: 
PVP, Povidone, Polyvidone 
Description: 
PVP is soluble in water and other polar solvents. When dry it is a light flaky 
powder, which readily absorbs up to 40% of its weight in atmospheric water. In 
solution, it has excellent wetting properties and readily forms films. This makes it 
good as a coating or an additive to coatings. 
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Structural formula: 
 
Molecular formula: 
(C6H9NO)n 
Chemical name: 
 Polyvinylpyrrolidine  
Melting point: 
150-180
0
c 
Functional category: 
It is used as a binder in many pharmaceutical tablets 
Apparent density: 
1.2 g/cm³ 
Solubility: 
  Soluble in hot and cold  water. 
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Stability and storage conditions: 
Stable, Incompatible with strong oxidizing agents, Light sensitive, 
Hygroscopic. 
Store at room temperature. 
Safety: 
It is generally considered safe. However, there have been documented cases of 
allergic reactions to PVP/Povidone, particularly regarding subcutaneous (applied 
under the skin) use and situations where the PVP has come in contact with autologous 
serum (internal blood fluids) and mucous membranes. 
Polyvinylpyrrolidine may cause interstitial fibrosis in the lungs. Lesions 
regress when patient is no longer being exposed to the compound. 
 
3.2.4 POLY VINYL ALCOHOL 
Non proprietary names: 
Poly (vinylis acetas),  Poly vinyl alcohol. 
Synonyms:  
Poly (Ethenol), Ethenol, Homopolymer, PVA, Polyviol, Vinol, Alvyl, 
Alkotex, Covol, Gelvatol, Lemol, Mowiol. 
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Description: 
  Polyvinyl alcohol occurs as an odorless, white to cream-colored granular 
powder. 
Structural formula: 
 
Chemical name: 
Poly Vinyl Alcohol 
Molecular formula: 
CH2CHOH 
Molecular weight: 
(44.05) n g/mole 
Functional category: 
Coating agent, lubricant, stabilizing agent, viscosity-increasing agent. 
Apparent density: 
1.19-1.31 g/cm³ 
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Solubility: 
Soluble in cold water, hot water. Insoluble in diethyl ether, acetone, petroleum 
solvents, aromatic hydrocarbons, esters. 
Practically insoluble in animal and vegetable oils and chlorinated 
hydrocarbons. 
Melting Point: 
Softens at about 200°C (392°F) with decomposition. Decomposition at 228
0
C. 
Incompatibilities: 
 Reactive with oxidizing agents, metals, acids, alkalis. 
Safety: 
Polyvinyl alcohol is generally considered a nontoxic material. It is nonirritant 
to the skin and eyes at concentrations up to 10%, concentrations up to 7% are used in 
cosmetics. 
Storage: 
Keep container tightly closed. Keep container in a cool, well-ventilated area. 
 
3.2.5 PROPYLENE GLYCOL 
Non-proprietary names: 
  Propylenglycolum, Propylene glycol 
Synonyms: 
2-hydroxypropanol; methyl ethylene glycol; methyl glycol; propane-1,2-diol. 
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Description: 
Propylene glycol is a clear, colorless, viscous, practically odorless liquid with 
a sweet, slightly acrid taste resembling that of glycerin. 
Structural formula: 
 
Chemical name: 
1, 2-Propanediol 
Molecular weight: 
76.09 
Functional category: 
Antimicrobial preservative, Disinfectant, Humectants, Plasticizer, Solvent, 
Stabilizer for vitamins, Water-miscible co solvent. 
Apparent density: 
1.038 g/cm
3
 at 208
0
C 
Solubility: 
Miscible with acetone, chloroform, ethanol (95%), glycerin, and water; 
soluble at 1 in 6 parts of ether; not miscible with light mineral oil or fixed oils, but 
will dissolve some essential oils. 
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Viscosity: 
58.1 mPas (58.1 cP) at 208
0
C 
Stability and storage conditions: 
At cool temperatures, propylene glycol is stable in a well-closed container, but 
at high temperatures, in the open, it tends to oxidize, giving rise to products such as 
propionaldehyde, lactic acid, pyruvic acid, and acetic acid. Propylene glycol is 
chemically stable when mixed with ethanol (95%), glycerin, or water; aqueous 
solutions may be sterilized by autoclaving. Propylene glycol is hygroscopic and 
should be stored in a well-closed container, protected from light, in a cool, dry place. 
Incompatibilities: 
Propylene glycol is incompatible with oxidizing reagents such as potassium 
permanganate. 
Safety: 
Propylene glycol is used in a wide variety of pharmaceutical formulations and 
is generally regarded as a relatively nontoxic material. 
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4.1 RESEARCH OBJECTIVE 
Transmucosal route of drug delivery have more advantages than oral 
administration for systemic drug delivery. Oral mucosal drug delivery is the route 
designed to deliver a therapeutically effective amount of drug across the mucosal 
surface of a patient and will have the following advantages. 
• Better bioavailability 
• Bypassing first-pass metabolism. 
• Avoidance of presystemic elimination of drug in GIT. 
• Reduction of side effects. 
• To produce controlled release of drug. 
• Localization of drug to oral cavity. 
• An ideal route of administration of drug for pregnant ladies and post 
operative vomiting. 
Dimenhydrinate is a member of drug belonging to the class of H1 anti 
histamine used in treatment of post operative vomiting. Dimenhydrinate undergoes 
first pass metabolism in the liver and as a consequence the availability of 
Dimenhydrinate in general circulation is low and variable. 
Physicochemical properties of Dimenhydrinate like small dose lipophilicity, 
stability at buccal P
H
, tasteless odorless and more absorption through buccal mucosa 
makes it an ideal candidate for administration by buccal route. 
Hence in the present work an attempt is being made to formulate a buccal 
muccoadhesive dosage form for Dimenhydrinate in the form of buccal patches by 
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using four different polymers Hydroxy Propyl Methyl Cellulose (HPMC), Hydroxy 
Ethyl Cellulose (HEC), Poly Vinyl Alcohol (PVA), Poly Vinyl Pyrolidine (PVP) to 
overcome the Hepatic metabolism and low bioavailability. 
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4.2 PLAN OF WORK 
1. Preformulation studies 
a) Solubility determination 
b) Melting point determination. 
c) Compatibility studies between Dimenhydrinate and polymers used. 
2. Preparation of standard curve for Dimenhydrinate. 
3. Formulation of buccal patches of Dimenhydrinate using different polymers in 
different concentrations. 
4. Evaluation of muccoadhesive buccal patches for following parameters 
a) Physical parameters 
i. Thickness 
ii. Folding endurance 
iii. Measurement of surface PH 
iv. Water uptake study 
b) Performance parameters 
i. Drug content uniformity 
ii. Measurement of bioadhesive strength 
iii. Mechanical strength 
iv. Scanning electron microscopy (SEM) 
v. In-vitro release study 
vi. Invitro residence time 
vii. Ex-vivo drug release study 
viii. Stability study 
ix. Kinetic study 
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The results are presented in tables and graphically by various equations 
governing release kinetics. 
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5. METHODOLOGY 
 The following materials & instruments were used for the preparation of 
Dimenhydrinate buccal patches. 
Table No. 1: LIST OF CHEMICALS USED  
S.no Name Grade supplier 
1 Dimenhydrinate Pharma Aurabindo 
pharmaceuticals. 
2 HPMC E15 USP/EP Alkem laboratories 
3 Hydroxy ethyl 
cellulose 
Laboratory SD Fine Chemicals 
Ltd. Mumbai. 
4 Poly vinyl alcohol Laboratory SD Fine Chemicals 
Ltd. Mumbai. 
5 Poly vinyl 
pyrolidine 
Laboratory SD Fine Chemicals 
Ltd. Mumbai. 
6 Propylene glycol Laboratory SD Fine Chemicals 
Ltd. Mumbai. 
7 Potassium 
dihydrogen 
phosphate 
Laboratory SD Fine Chemicals 
Ltd. Mumbai. 
8 Disodium hydrogen 
phosphate 
Laboratory SD Fine Chemicals 
Ltd. Mumbai. 
9 Distilled water Laboratory ----- 
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LIST OF INSTRUMENTS 
Table No.2: LIST OF INSTRUMENTS USED  
S.no. Name supplier 
1. Magnetic Stirrer NEBO, India. 
2. Electronic Digital Balance SCHIMADZU, Japan. 
3. 
Teflon coated Magnetic 
Beads 
Modern Scientific Works, 
Coimbatore. 
4. Digital P
H
 Meter. SYSTRONIC, Chennai 
5. Franz diffusion cell Glass works, New Delhi. 
6. 
Double Beam UV/VIS 
Spectrophotomèter. 
SYSTRONIC, Chennai 
7. Hot Air Oven KEMI, India. 
8. Vaccum Dessicator Polylab, India 
9. FT-IR Perkin Elmer, US. 
10. Incubator KEMI, India 
11. Screwguage SOMET INOX, INDIA 
12. Whatmann filter paper Minisart, Germany 
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1. PREFORMULATION STUDIES: 
 Preformulation testing first step in development of dosage forms of a drug. It 
is defined as an investigation of physical chemical properties of drug substance alone 
and when combined with excipients. The overall concept of preformulation testing is 
to generate information useful to the formulator in developing stable and bioavailable 
dosage forms. 
 The goals of the Preformulation studies are: 
• To establish the necessary physicochemical properties of a new drug 
substance. 
• To determine its kinetic release profile. 
• To establish its compatibility with different excipients. 
Hence, Preformulation studies on the obtained sample of drug include physical 
tests and compatibility studies. 
A. Identification tests: 
 IR spectroscopy: The IR spectrum of the obtained sample of drug was 
compared with the IR spectra of the pure drug. 
 Solubility analysis: Solubility analysis was done to select a suitable solvent 
system to dissolve the drug and to test its solubility in the dissolution medium, 
witch was to be used. 
 Melting point determination: Melting point of drug sample was determined 
by capillary tube method. 
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B. Compatibility studies of Dimenhydrinate and polymers: 
 FT-IR spectrum of drug and physical mixture of drug with polymers were 
obtained. The samples were mixed with KBr and the spectrum was obtained by 
scanning over the wave number range of 4000-400cm
-1
. IR helps to confirm the 
identity of the drug and to detect the interaction of the drug with the excipients. 
C. Calibration curve. 
A. Scanning of drug: 
Accurately weighed 100mg of Dimenhydrinate and dissolved in 10ml of 
methanol and make up the volume to 100ml with distilled water. Take one ml from 
the above solution and make up the volume to 100ml with distilled water having 
concentration of 10mcg/ml 
The absorption maxima of the above standard solution was scanned between 
200-400nm in UV spectrophotometer against blank. The absorption maxima were 
found to be 276nm.  
B. Preparation of calibration curve of Dimenhydrinate  
From the above standard solution aliquots of 1,2,3,4,5,6,7,8,9,10ml was 
withdrawn and the volume make up to 10ml with distilled water to get the 
concentration of 1-10mcg/ml respectively. Absorbances of these solutions were 
measured against blank at 276nm. 
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PREPARATION OF BUCCAL PATCHES: 
 Patches containing Dimenhydrinate and HPMC E15, HEC, PVP, PVA 
different proportions was prepared by the solvent casting method. The drug was 
dissolved in 5ml of methanol and the polymers were dissolved in separate container 
with 20ml of distilled water under continuous stirring for 4 hours. After stirring, mix 
the drug and polymer solution. Propylene glycol was added into the solution as a 
plasticizer under constant stirring. The viscous solution was left over night to ensure a 
clear, bubble free solution. The solution was poured into a glass petridish and allowed 
to dry at 40
0
c temperature till a flexible patch was formed. Dried patch was removed 
carefully, checked any imperfections or air bubbles and cut into pieces of 1mm
2
 area. 
The patches were packed in aluminum foil and stored in desiccators to maintain the 
integrity and elasticity of the patches. Table no.3 shows the composition of different 
buccal patches. 
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Table no. 3: composition of buccal patches of Dimenhydrinate. 
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 
Dimenhydrin
ate 
250
mg 
250
mg 
250
mg 
250
mg 
250
mg 
250
mg 
250
mg 
250
mg 
250
mg 
250 
mg 
HPMC E15 750
mg 
---- 250
mg 
375
mg 
500
mg 
750
mg 
---- 250
mg 
375
mg 
500 
mg 
HEC ---- 750
mg 
500
mg 
375
mg 
250
mg 
---- 750
mg 
500
mg 
375
mg 
250 
mg 
PVP 125
mg 
125
mg 
125
mg 
125
mg 
125
mg 
---- ---- ---- ---- ---- 
PVA ---- ---- ---- ---- ---- 125
mg 
125
mg 
125
mg 
125
mg 
125 
mg 
ETHANOL 5ml 5ml 5ml 5ml 5ml 5ml 5ml 5ml 5ml 5ml 
Propylene 
glycol 
0.7 
ml 
0.7 
ml 
0.7 
ml 
0.7 
ml 
0.7 
ml 
0.7 
ml 
0.7 
ml 
0.7 
ml 
0.7 
ml 
0.7 ml 
Distilled 
water 
25ml 25ml 25ml 25ml 25ml 25ml 25ml 25ml 25ml 25ml 
 
 
 
 
 
 
 
 
 
Chapter-5                                                                                                                 Methodology 

Dept. of Pharmaceutics, The Erode College of Pharmacy & Research Institute  


EVALUATION OF MUCCOADHESIVE BUCCAL PATCHES OF 
DIMENHYDRINATE 
 Physical parameters 
v. Thickness 
vi. Folding endurance 
vii. Measurement of surface PH 
viii. Water uptake study 
 Performance parameters 
x. Drug content uniformity 
xi. Measurement of bioadhesive strength 
xii. Mechanical strength 
xiii. Scanning electron microscopy (SEM) 
xiv. In-vitro release study 
xv. Invitro residence time 
xvi. Ex-vivo drug release study 
xvii. Stability study 
xviii. Kinetic study 
A. PHYSICAL PARAMETERS: 
a) Thickness of patch: 
 Thickness of patch was measured at 5 different randomly selected spots using 
screw gauge. The mean and standard were calculated. 
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b) Folding endurance: 
Folding endurance of the buccal patches was determined by taking 20mm 
diameter of patch was repeatedly folding at the same place till it broke. The no of 
times of patch could be folded at the same place without breaking gave the value of 
the folding endurance. The test was done three times and calculates the mean and 
standard. 
c) Mechanical strength: 
Mechanical properties of patches were evaluated by using the microprocessor 
based advanced force gauze equipped with a motorized test stand equipped with cell. 
Patch with diameter 60×10mm and without any visual defects were cut and positioned 
between two clamps separated by a distance 3cm. clamps were designed to secure the 
patch without crushing it during test, the lower clamp was held stationary and the 
strips were pulled apart by the upper clamp moving at a rate 2mm/sec until the patch 
broke. The force and elongation of the film at the point when the patch broke was 
recorded. The tensile strength and elongation at break values were calculated using 
the formula. 
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WATER UPTAKE STUDY 
The moisture uptake studies give an indication about the relative moisture 
absorption capacities of polymers and an idea whether the formulations maintain their 
integrity after absorption of moisture. This test was carried out by dissolving 5% w/v 
agar in hot water. It was transferred into petriplates and it was allowed to solidify. Six 
drug free patches from each formulation were selected and weighed. They were 
placed in vacuum oven overnight prior to the study to remove moisture if any and 
laminated on one side with water impermeable backing membrane. They were then 
incubated at 37
0
 C for one hour, removed and reweighed. The percentage moisture 
absorption was calculated by using the formula. 
 
 
This test was performed in triplicate. 
Surface p
H
 
For determination of surface pH three films of each formulation were allowed 
to swell for 2 h on the surface of an agar plate. The surface P
H
 was measured by using 
a P
H
 paper placed on the surface of the swollen patch. A mean of three readings was 
recorded. 
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B. PERFORMANCE PARAMETERS: 
a) Drug content uniformity: 
Drug content uniformity was calculated by taking three film units of each 
formulation were taken in separate 100 ml volumetric flasks, 100 ml of P
H
 6.8 
phosphate buffer was added and continuously stirred for 24 hrs. The solutions were 
filtered, diluted suitably and analyzed at 276nm in a UV spectrophotometer 
(Sysronic). The average of drug contents of three films was taken as final reading. 
b) Measurement of bioadhesive strength: 
The force required to detach the bioadhesive films from the mucosal surface 
was applied as a measure of the bioadhesive performance. Bioadhesive strength of the 
patches was examined by the slightly modified procedure using the porcine gastric 
mucosa as the model membrane. The instrument is broadly composed of a modified 
two arm physical balance in which the right pan had been replaced by a formulation 
holding glass plate and counter balanced by a water collecting pan suspended to the 
left arm. The pan received a siphon tube from a 10 L bottle, which was kept at a high 
place in such a way that water head in the bottle, always remains above the water 
collecting pan. The siphon tube bears a flow regulating device. Nylon thread was used 
to suspend both the glass plate and the pan. An acrylate tissue mounting stage was 
attached to the center of a glass beaker. Glass beaker was filled with phosphate buffer 
(P
H
 6.8) to simulate in-vivo saliva conditions. A magnetic stirrer provided with 
temperature control was used to maintain the temperature of phosphate buffer (P
H
 6.8) 
in glass dish at 37±0.5 °C. A piece of porcine gastric mucosa, 3 cm long, was tightly 
secured on the upper surface of the acrylate tissue mounting stage with thread. Films 
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were fixed on the centre of the formulation holding glass plate with an adhesive. The 
exposed film surface was moistened with phosphate buffer (P
H
 6.8) and left for some 
time for initial hydration and swelling. Then glass plate (with the film) was kept on 
the mucosal tissue secured on the tissue mounting stage in such a way that films 
completely remained in contact with mucosa. The whole assembly was kept 
undisturbed for few minutes (preload time) to establish the adhesion between the film 
and mucosal tissue. The glass plate (weight 50 g) itself acted as a preload. After the 
preload time, water collecting pan was suspended to the left arm and water was added 
in it, by the siphon tube, at a constant rate of 200 drops per minute until detachment of 
the film from mucosal surface took place. A support was kept under the water 
collecting pan to hold it at the time of detachment. Weight of water collected in the 
pan at the time of detachment was measured. The experiment was performed in 
triplicate. 
Measurement of in vitro Residence Time 
The in vitro residence time was determined by using modified USP 
disintegration apparatus. The disintegration medium was 800 ml of isotonic 
Phosphate buffer solution (P
H
 6.8) taken and maintained at temperature 37±2
0
C. The 
segments of porcine buccal mucosa, each of 3 cm length, were glued to the surface of 
a glass slab, which was then vertically attached to the apparatus. Three 
muccoadhesive films of each formulation were hydrated on one surface using isotonic 
Phosphate buffer solution (P
H
 6.8) and the hydrated surface was brought into contact 
with the mucosal membrane. The glass slab was vertically fixed to the apparatus and 
allowed to move up and down. The film was completely immersed in the buffer 
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solution at the lowest point and was out at the highest point. The time required for 
complete erosion or detachment of the film from the mucosal surface was recorded. 
Scanning electron microscopy: 
SEM has been used to determine the particle size distribution, surface texture 
and to examine the morphology of the fractured or sectioned surface. The same 
generally used for generating three dimensional surface relief images derived from 
secondary electrons. The examination of surface of polymeric drug delivery can 
provide important information about the porosity and microtecture of device. 
Invitro release study by dissolution 
[4]
: 
 The US pharmacopoeia XXIII rotating paddle method was used to study and 
calculate the drug release from the buccal patches, 500ml of phosphate buffer used as 
the dissolution medium at 37±0.5
0
c and a rotation speed 50RPM was used. Patches of 
1cm
2
 area were cutted and sandwiching the patch in dialysis membrane. A piece of 
glass slide was placed as support to prevent the assembly from floating. The dialysis 
membrane tubing with patch inside was secured from both ends using closure clips, 
then it was placed in the bottom of the vessel containing phosphate buffer having p
H
 
6.8. Samples 5ml were withdrawn at a specific time interval and replaced with fresh 
buffer medium. The samples were filtered using whatmann filter paper and analyzed 
by using UV spectrophotometer at 276nm. The experiments were performed triplicate 
and average values were calculated and reported. 
Ex-vivo release study 
[4]
: 
Ex-vivo release studies performed by using the buccal tissue from porcine was 
collected from slaughter house. The tissue was excised to remove fat and muscle 
using scalpel and then placed in phosphate buffer p
H
 7.4. The buccal epithelium was 
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carefully mounted between two compartments of Franz diffusion cell with internal 
volume 60ml. Phosphate buffer p
H
 7.4 was placed in receptor compartment and the 
donor compartment containing 4ml of phosphate buffer in which the drug was 
dissolved. The entire setup was placed on magnetic stirrer and temperature maintained 
at 37
0
c.  The patch was moisten and attached to the buccal mucosa. The epithelium 
with buccal patch was placed between the two compartments. Samples of 3ml was 
collected from the receptor side at predetermined time interval and replaced with 
equal amount of fresh buffer solution. The samples were analyzed by using UV 
spectrophotometer at 276nm.  
Stability studies: 
Stability of a drug has been defined as the ability of a particulate formulation, 
in a specific container, to remain with in its physical, chemical, therapeutic and 
toxicological specifications. 
 The purpose of stability testing is to provide evidence on how the quality of a 
drug substance or drug product varies with time under the influence of a variety of 
environmental factors such as temperature, humidity and light, and enables 
recommended storage conditions. 
ICH specifies the length of study and storage conditions: 
 Long term testing – 25
0
c±2
0
c/ 60%±5% RH for 12 months 
 Accelerated testing – 40
0
c±2
0
c/ 75%±5% RH for 6 months 
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Procedure: 
 In the present study, stability studies were carried out for a specific time 
period up to 90days, for selected formulations at 40
0
c±2
0
c/ 75%±5% RH in humidity 
control oven for 30days. 
The selected formulation F3 was analyzed for the physical parameters like 
general surface pH, water absorption studies and performance parameters like drug 
content uniformity, Invitro dissolution studies, and Ex-vivo permeation study. 
Kinetic study: 
 The matrix systems were reported to follow the zero order release rate and the 
diffusion mechanism for the release of the drug. To analyze the mechanism for the 
release and release rate kinetics of the dosage form, the data obtained was fitted into, 
Zero order, First order, Higuchi matrix and peppa’s model. In this by comparing the r-
values obtained, the best fit model was selected. 
1. Zero order kinetics: 
 Drug dissolution from pharmaceutical dosage forms that do not disaggregate 
and release the drug slowly, assuming that the area does not change and no 
equilibrium conditions are obtained can be represented by the following equation 
Qt = Qo + Kot 
Where Qt  is the amount of drug dissolved in time t, Qo is the initial amount of 
drug in the solution and Ko is the zero order release constant. 
2. First order kinetics: 
 To study the first order release kinetics the release rate data were fitted to the 
following equation. 
Log Qt = log Qo+ k1t/2.303. 
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Where Qt is the amount of the drug released in time t, Qo is the initial amount 
of the drug in the solution and K1 is the first order release constant.     
3. Higuchi model: 
 Higuchi developed several theoretical models to study the release of water 
soluble and low soluble drugs incorporated in semisolids and or solid matrices. 
Mathematical expressions were obtained for drug particles dispersed in a uniform 
matrix behaving as the diffusion media. And the equation is 
Qt = KH . t
1/2 
Where Qt is the amount of drug released in time t, KH is the Higuchi 
dissolution constant. 
4. Korsmeyer and Peppa’s model: 
To study this model the release rate data are fitted to the following equation. 
Mt/M =K.t
n 
 Where Mt/M is the fraction of drug release, K is the release constant, t is the 
release time and n is the Diffusional exponent for the drug release that is dependent 
on the shape of the matrix dosage form. 
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6. RESULTS 
1. Preformulation studies: 
A. Identification of pure drug: 
IR Spectroscopy: 
The IR spectrum of pure drug of Dimenhydrinate shows the following functional 
groups at their frequencies. The IR spectra of Dimenhydrinate shown in spectrum 
no.1 
Table No. 4 Interpretation of IR spectra 
S.no Functional group IR range 
Assessment of 
peak(cm
-1
) 
1 
C-H Stretching in 
CH3 group 
1020-1220 1041.60 
2 
C-H Stretching in 
aromatic ring 
3100-3000 3030.27 
3 
N-H Stretching in 
Hetero aromatic 
ring 
3500-3220 3329.25 
4 
C-Cl Stretching of 
mono chlorinated 
aromatic compound 
750-700 702.11 
5 
C-H Stretching in 
Methoxy group 
2815-2850 2818.09 
6 
C-H Bending 
vibration in CH2 
group of R-CH2-N= 
1475-1445 1462.09 
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Spectrum No.1: FT-IR Spectra of drug (Dimenhydrinate) 

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Spectrum No.2: FT-IR Spectra of drug (Dimenhydrinate) + HPMC E15

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Spectrum No.3: FT-IR Spectra of drug (Dimenhydrinate) + HEC

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Spectrum No.4: FT-IR Spectra of drug (Dimenhydrinate) + PVP
Spectrum No.5: FT-IR Spectra of drug (Dimenhydrinate) + PVA
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Solubility study:
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                 The approximate solubility’s of substances are indicated by the descriptive 
terms in the accompanying table no 7. 
Table no .5 Descriptive term for solubility 
Descriptive term Parts of solvent required for 1 part of 
solute 
Very soluble Less than 1 
Freely soluble From 1 to 10 
Soluble From 10 to 30 
Sparingly soluble From 30 to 100 
Slightly soluble From 100 to 1000 
Very slightly soluble From 1000 to 10000 
Practically in soluble or insoluble Greater than or equal to 10000 
 
1. Dimenhydrinate – soluble in methanol, ethanol and water, insoluble in acids. 
Melting point determination: 
The melting point of the drug sample was found to be, which is with in the reported 
value of 104
0
c.it complies with standards thus indicating the purity of drug sample. 
Drug –excipients compatibility studies: 
        From IR spectra of pure drug and the combination of pure drug with 
polymers, shows that all the characteristic peaks of Dimenhydrinate were present in 
the combination spectrum thus indicating compatibility of the drug and polymer. 
        IR spectra of pure drug and in combination with the polymers are shown in 
spectrum. 
Calibration curve of Dimenhydrinate in distilled water: 
Table no.7 shows the absorbance of Dimenhydrinate standard solution 
containing 1-10mcg/ml of drug in distilled water. Graph no shows a representative 
calibration curve with slope and regression coefficient, 0.018 and 0.999 respectively. 
The curve was found to be linear in the range of 1-10mcg/ml at absorbance maxima 
276nm. 
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Spectrum No.6: Absorption maxima scanning of Dimenhydrinate. 
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TABLE NO.7:  STANDARD CURVE OF DIMENHYRINATE USING DISTILLED 
WATER. 
S.NO Concentration(mcg/ml) Absorbance 
1 0 0 
2 1 0.018 
3 2 0.036 
4 3 0.055 
5 4 0.073 
6 5 0.092 
7 6 0.111 
8 7 0.129 
9 8 0.148 
10 9 0.165 
11 10 0.184 


Graph No.5: STANDARD CALIBRATION CURVE FOR DIMENHYRINATE IN 
DISTILLED WATER.


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EVALUATION PARAMETERS: 
Physical properties: 
Thickness of patch: 
 The thickness of the prepared buccal patches of each formulation was 
determined with in the range of 0.23- 0.26mm. Is given in table no.8. 
Folding endurance: 
The folding endurance of each formulation was determined with in the range 
of 302 to 318. Is given in table no.8. 
Mechanical strength: 
Three patches of each formulation were evaluated and mean values are 
recorded in table no.8. The values were found to be in the range of 5.28 to 
12.94kg/mm
2
. The values revealed that the patches were having good mechanical 
strength. 
Water uptake study: 
Water uptake of all buccal patches containing Dimenhydrinate is given in 
table no.8. These values represent the mean of three replicate determinations. The 
values were found to be with in the range of 1.93 to 2.93. The percentage water 
absorption of the respective patches was determined at Third hour. 
Table.no.8: Evaluation of Physical parameters of different mucoadhesive buccal 
patches of Dimenhydrinate. 
Physical parameters Formulation 
code Thickness 
(mm) 
±S.D (n=3) 
Folding 
endurance 
±S.D (n=3) 
Mechanical 
strength 
±S.D (n=3) 
(kg/mm
2
) 
Water 
uptake 
±S.D (n=3) 
F1 0.23± 0.005 305± 4.04 5.28± 0.076 2.15± 0.64 
F2 0.22± 0.014 305± 4.72 6.04± 0.056 2.02± 0.52 
F3 0.24± 0.002 313± 2.51 12.94± 0.098 2.93± 0.102 
F4 0.26± 0.0023 318± 2.51 12.64± 0.124 2.53± 0.23 
F5 0.25± 0.001 302± 1.00 10.86± 0.132 1.95± 0.051 
F6 0.23± 0.003 312± 2.51 6.84± 0.079 1.93± 0.153 
F7 0.24±  0.023 318± 2.52 7.23± 0.32 2.07± 0.354 
F8 0.26± 0.01 310± 5.50 9.45± 0.054 2.18± 0.243 
F9 0.26± 0.034 309± 5.51 12.14± 0.045 2.46± 0.109 
F10 0.25± 0.023 304± 4.50 11.96± 0.091 2.00± 0.63 
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Performance parameters: 
Content uniformity of active ingredient: 
Table no.9.2 shows the result of drug content uniformity in each formulation. 
Three replicates of each test were carried out. The mean drug content was found to be 
in the range of 3.68 to 3.8 for (each patch size 10mm diameter) the prepared buccal 
patch formulations. 
Measurement of bioadhesive strength: 
An effective buccal mucosal device must maintain an intimate contact with 
mucus layer overlying the epithelial tissue. This parameter very important to 
successful utilization of these dosage forms. Hence in-vitro evaluation of buccal 
patches was carried out using porcine gastric mucosa. This gives the indirect 
measurement of bioadhesive strength in grams.  
Table no9.1 represents the bioadhesive strength of the each formulation of 
buccal patches. The mean bioadhesive strength values were found to be 144.3, 
149.34, 187.67, 176.28, 167.33, 132.64, 134.23, 167.35, 168.23 and 159.46 for F1 to 
F10 respectively. 
          Force on adhesion (N) 1.40, 1.44, 1.82, 1.62, 1.75, 1.62, 1.42, 1.47, 1.76 and 
1.12 (N) for F1 to F10 respectively. Bond strength (Nm
-2
) 453.08, 432.12, 586.09, 
543.63, 513.78, 421.12, 435.47, 564.65, 523.34 and 498.21 (Nm
-2
) for F1 to F10 
respectively.  
Measurement of surface P
H
  :  
Table no9.2 shows the result of surface ph values for each formulation. These 
values represent the mean of three replicate determinations. They were found to be 
with in the range of 6.3 to 6.6 for all formulations and were almost with in the range 
of salivary p
H
 i.e. 6.2 to 7.4. It represents the better patient acceptability. 
 
 
 
 
 
 
 
Chapter-6                                                                                                 Results and discussion 

Dept. of Pharmaceutics, The Erode College of Pharmacy & Research Institute  

 
Table .no.9.1: Evaluation of Performance parameters of different mucoadhesive 
buccal patches of Dimenhydrinate. 
Performance parameters(Bio adhesive) Formulation code 
Bioadhesive 
strength(gms) 
±S.D (n=3) 
Force of 
adhesion(N)  ±S.D 
(n=3) 
Bond strength 
±S.D (n=3) 
(kg/mm2) 
F1 144.3± 2.64 1.40± 0.03 453.02± 5.34 
F2 149.34± 2.13 1.44± 0.02 432.12± 3.65 
F3 187.67± 0.78 1.82± 0.05 586.09± 5.23 
F4 176.28± 0.98 1.62± 0.01 543.63± 1.86 
F5 167.33± 1.34 1.75± 0.01 513.78± 4.33 
F6 132.64± 3.67 1.62± 0.06 421.12± 6.98 
F7 134.23± 2.87 1.42± 0.04 435.47± 5.32 
F8 167.35± 1.74 1.47± 0.03 564.65± 6.90 
F9 168.23± 1.53 1.76± 0.01 523.34± 3.23 
F10 159.46± 1.13 1.12± 0.01 498.21± 4.98 
 
Table No.9.2: Evaluation of Performance parameters of different mucoadhesive 
buccal patches of Dimenhydrinate. 
 
Performance parameters(Bio adhesive) Formulation code 
Drug content(mgs) 
±S.D (n=3) 
Surface P
H
  ±S.D 
(n=3) 
Invitro residence 
time (min)±S.D 
(n=3) 
(kg/mm2) 
F1 3.73± 0.23 6.3± 0.54 320±10 
F2 3.78± 0.13 6.4± 0.43 350±5 
F3 3.71± 0.011 6.6± 0.57 490± 15 
F4 3.80± 0.54 6.5± 0.43 420± 5 
F5 3.75± 0.36 6.4± 0.57 450±10 
F6 3.69± 0.45 6.4± 0.57 310±10 
F7 3.68± 0.98 6.6±  0.23 300± 10 
F8 3.76± 0.21 6.3± 0.45 421± 15 
F9 3.73± 0.11 6.6± 0.34 480± 5 
F10 3.78± 0.78 6.4± 0.23 430± 10 
 
In vitro release study: 
The in-vitro dissolution was studied in phosphate buffer p
H
 6.8. The Invitro 
dissolution studies were carried out in triplicate and the results shown in the tables are 
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mean of the replicate values. The Invitro released data obtained for patches F1 to F10 
are tabulated in table no.10 to 19 respectively 
The results of Invitro dissolution studies obtained in these formulations were floated 
in 4 models of data treatments as follows 
1. Cumulative percentage of drug released Vs time. (Zero order) 
2. Log cumulative percentage of drug retained Vs time. (First order) 
3. Cumulative percentage of drug released Vs square root of time. (Higuchi’s plot) 
4. Log cumulative percentage of drug released Vs log of time. (Peppa’s plot) 
Graph shows the plot of cumulative percentage of drug released as a function 
of time for different buccal patches. Cumulative percentage drug released as found to 
be 99.78% (8 hours), 99.58% (7 hours), 99.49% (10 hours), 100.17 (9 hours), 
100.18% (9 hours), 97.15% (8 hours), 98.54% (8 hours), 100.75% (10 hours), 99.67% 
(9 hours) and 100.6% (9 hours) for F1 to F10 respectively. The plot for cumulative 
percentage drug release verses time for all formulations are shown in graph no 6 to 
24, and comparative cumulative release shown in graph no. 26. 
Stability study: 
Stability studies of  the prepared buccal patches were carried out, by storing 
formulations F5 at, room temperature and humidity and 40
0
 C+ 2
0
C/75%RH + 5% 
RH in humidity control oven for ninety days. Stability studies were carried out to 
predict the degradation that may occur over prolonged periods of storage at various 
temperatures and humidity for formulations F5 over a period of 90 days. The results 
of the stability studies, which were conducted for 90 days, are shown in table no.24. 
The result obtained showed a slight decrease in, in vitro release of formulations F5 as 
compared to the fresh formulations F5. The shelf life of the fabricated device was 
calculated based on these parameters. 
Kinetic study: 
        To study the drug release kinetics, data obtained from In-Vitro drug release 
studies are plotted in various kinetic models. 
 
i) Zero order:  
It is plotted as cumulative amount of drug released Vs time. 
C=K0 t 
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Where K0 is the zero order rate constant expressed in units of concentration by time. 
T is the time in hours. 
A graph of concentration Vs time would yield a straight line with a slope equal 
to k0 and the intercept at the origin of the axis. 
ii) First order: 
It is plotted as log cumulative percentage of drug remaining Vs time.  
LogC = LogC0 – Kt/2.303 
Where Co is the initial concentration of drug, K is the first order constant, t is 
the time in hours. 
iii) Higuchi model: 
It is plotted as cumulative percentage of drug release Vs square root of time. 
Q=Kt
1/2
 
   Where K is the constant reflecting the design variables of the system, t is the 
time in hours. 
Hence, release rate is proportional to the reciprocal of square root of time t. 
iv) Korsmeyer and Peppa’s: 
  As log cumulative percentage of drug released Vs square root of time, and the 
exponent n is calculated through the slope of the straight line. 
Mt/M= Kt
n
 
Where Mt/M is the fractional solute release, T is the release time, K is a 
kinetic constant characteristic of the drug/polymer system and is an exponent that 
characterizes the mechanism of release of tracers  
The slope n was computed to know whether the release was Fickian or Non-
Fickian. For Non-Fickian release the n values falls between 0.5 and 1.0 , while for 
Fickian diffusion n is less than or equal to 0.5. The slope values are tabulated in table 
no.22. The values of n were more than 0.5 for all formulations. 
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Table no. 6 Diffusional   n values 
N Mechanism 
0.5 
 
0.5<n<1 
 
1 
Fickian diffusion 
 
Non-Fickian diffusion 
 
Case II transport 
n is the Diffusional exponent and is also an important indicator of transport of 
drug through the polymer. 
The model fitting graphs for each formulation are shown in graph no.7 to 25.   
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Table No.10: Invitro Drug Release of mucoadhesive buccal patches of 
DimenhydrinateF1 
Time in 
hrs 
Log time SQ.RT of 
time 
Abs 
(276nm) 
Cum% 
release 
Log cum% 
release 
0 0.000 0.000 0.000 0.000 0.000 
0.5 -0.301 0.707 0.016 11.59 1.064 
1 0.000 1.000 0.027 19.67 1.294 
2 0.301 1.414 0.047 34.36 1.536 
3 0.477 1.732 0.061 44.85 1.651 
4 0.602 2.000 0.085 62.68 1.797 
5 0.698 2.236 0.101 74.89 1.874 
6 0.778 2.449 0.112 83.59 1.922 
7 0.845 2.645 0.123 92.37 1.965 
8 0.903 2.828 0.132 99.78 1.999 
 
Graph No.6: Dissolution profile for Formulation F1 
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Graph No.7: (a) Zero order Drug Release Kinetics for Formulation F1 
 
(a) First order Drug Release Kinetics for Formulation F1 
 
(a) Higuchi’s Drug Release Kinetics for Formulation F1 
 
(D) Korsmeyer-Peppa’s Drug Release Kinetics for Formulation F1 
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Table. No.11: Invitro Drug Release of mucoadhesive buccal patches of 
DimenhydrinateF2 
Time in 
hrs 
Log time SQ.RT of 
time 
Abs 
(276nm) 
Cum% 
release 
Log cum% 
release 
0 0.000 0.000 0.000 0.000 0.000 
0.5 -0.301 0.707 0.023 16.4 1.214 
1 0.000 1.000 0.045 32.25 1.508 
2 0.301 1.414 0.065 46.83 1.670 
3 0.477 1.732 0.087 62.98 1.799 
4 0.602 2.000 0.105 76.44 1.883 
5 0.698 2.236 0.112 82.18 1.914 
6 0.778 2.449 0.128 94.39 1.974 
7 0.845 2.645 0.134 99.58 1.998 
 
Graph No.8: Dissolution profile for Formulation F2 
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Graph No.9: (a) Zero order Drug Release Kinetics for Formulation F2 
 
(b) First order Drug Release Kinetics for Formulation F2 
 
(c) Higuchi's Drug Release Kinetics for Formulation F2 
 
(D) Korsmeyer-Peppa’s Drug Release Kinetics for Formulation F2 
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Table No.12: Invitro Drug Release of mucoadhesive buccal patches of 
DimenhydrinateF3 
Time in 
hrs 
Log time SQ.RT of 
time 
Abs 
(276nm) 
Cum% 
release 
Log cum% 
release 
0 0.000 0.000 0.000 0.000 0.000 
0.5 -0.301 0.707 0.013 9.47 0.976 
1 0.000 1.000 0.023 16.85 1.226 
2 0.301 1.414 0.043 31.58 1.499 
3 0.477 1.732 0.062 45.74 1.660 
4 0.602 2.000 0.073 54.20 1.734 
5 0.698 2.236 0.087 64.93 1.812 
6 0.778 2.449 0.099 74.31 1.871 
7 0.845 2.645 0.113 85.23 1.930 
8 0.903 2.828 0.119 90.42 1.956 
9 0.954 3.000 0.125 95.66 1.980 
10 1 3.162 0.129 99.49 1.998 
 
Graph No.10: Dissolution profile for Formulation F3 
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Graph No.11: (a) Zero order Drug Release Kinetics for Formulation F3 
 
(b) First order Drug Release Kinetics for Formulation F3 
 
(C) Higuchi's Drug Release Kinetics for Formulation F3 
 
(D) Korsmeyer-Peppa’s Drug Release Kinetics for Formulation F3 
 
Chapter-6                                                                                                 Results and discussion 

	
Dept. of Pharmaceutics, The Erode College of Pharmacy & Research Institute  

 
Table No.13: Invitro Drug Release of mucoadhesive buccal patches of 
DimenhydrinateF4 
Time in 
hrs 
Log time SQ.RT of 
time 
Abs 
(276nm) 
Cum% 
release 
Log cum% 
release 
0 0.000 0.000 0.000 0.000 0.000 
0.5 -0.301 0.707 0.015 10.66 1.028 
1 0.000 1.000 0.032 22.86 1.359 
2 0.301 1.414 0.043 30.91 1.490 
3 0.477 1.732 0.064 46.15 1.664 
4 0.602 2.000 0.072 52.30 1.718 
5 0.698 2.236 0.091 66.33 1.821 
6 0.778 2.449 0.112 81.91 1.913 
7 0.845 2.645 0.123 90.53 1.956 
8 0.903 2.828 0.132 97.8 1.990 
9 0.9542 3 0.135 100.17 2.000 
 
Graph No.12: Dissolution profile for Formulation F4 
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Graph No.13: (a) Zero order Drug Release Kinetics for Formulation F4 
 
(a) First order Drug Release Kinetics for Formulation F4 
 
(a) Higuchi’s Drug Release Kinetics for Formulation F4 
 
(D) Korsmeyer-Peppa’s Drug Release Kinetics for Formulation F4 
 
Chapter-6                                                                                                 Results and discussion 

	
Dept. of Pharmaceutics, The Erode College of Pharmacy & Research Institute  

 
Table. No.14: Invitro Drug Release of mucoadhesive buccal patches of 
DimenhydrinateF5 
Time in 
hrs 
Log time SQ.RT of 
time 
Abs 
(276nm) 
Cum% 
release 
Log cum% 
release 
0 0.000 0.000 0.000 0.000 0.000 
0.5 -0.301 0.707 0.011 7.92 0.899 
1 0.000 1.000 0.021 15.21 1.182 
2 0.301 1.414 0.029 21.13 1.324 
3 0.477 1.732 0.049 35.75 1.553 
4 0.602 2.000 0.075 54.84 1.739 
5 0.698 2.236 0.087 64.03 1.806 
6 0.778 2.449 0.096 71.14 1.852 
7 0.845 2.645 0.110 81.93 1.913 
8 0.903 2.828 0.123 92.09 1.964 
9 0.954 3.000 0.133 100.18 2.000 
 
Graph No.14: Dissolution profile for Formulation F5 
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Graph No.15: (a) Zero order Drug Release Kinetics for Formulation F5 
 
(b) First order Drug Release Kinetics for Formulation F5 
 
(a) Higuchi’s Drug Release Kinetics for Formulation F5 
 
(D) Korsmeyer-Peppa’s Drug Release Kinetics for Formulation F5 
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Table. No.15: Invitro Drug Release of mucoadhesive buccal patches of 
DimenhydrinateF6 
Time in 
hrs 
Log time SQ.RT of 
time 
Abs 
(276nm) 
Cum% 
release 
Log cum% 
release 
0 0.000 0.000 0.000 0.000 0.000 
0.5 -0.301 0.707 0.016 11.71 1.068 
1 0.000 1.000 0.023 16.96 1.229 
2 0.301 1.414 0.043 31.78 1.502 
3 0.477 1.732 0.056 41.61 1.619 
4 0.602 2.000 0.089 66.19 1.820 
5 0.698 2.236 0.102 76.37 1.882 
6 0.778 2.449 0.115 86.64 1.937 
7 0.845 2.645 0.121 92.87 1.963 
8 0.903 2.828 0.127 99.15 1.987 
 
Graph No.16: Dissolution profile for Formulation F6 
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Graph No.17: (a) Zero order Drug Release Kinetics for Formulation F6 
 
(a) First order Drug Release Kinetics for Formulation F6 
 
(c) Higuchi’s Drug Release Kinetics for Formulation F6 
 
(d) Korsmeyer-Peppa’s Drug Release Kinetics for Formulation F6 
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Table. No.16: Invitro Drug Release of mucoadhesive buccal patches of 
DimenhydrinateF7 
Time in 
hrs 
Log time SQ.RT of 
time 
Abs 
(276nm) 
Cum% 
release 
Log cum% 
release 
0 0.000 0.000 0.000 0.000 0.000 
0.5 -0.301 0.707 0.015 11.01 1.042 
1 0.000 1.000 0.024 17.73 1.248 
2 0.301 1.414 0.034 25.25 1.402 
3 0.477 1.732 0.053 39.46 1.596 
4 0.602 2.000 0.074 55.27 1.742 
5 0.698 2.236 0.089 66.83 1.824 
6 0.778 2.449 0.108 81.44 1.910 
7 0.845 2.645 0.121 91.78 1.962 
8 0.903 2.828 0.129 98.54 1.993 
 
Graph No.18: Dissolution profile for Formulation F7 
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Graph No.19: (a) Zero order Drug Release Kinetics for Formulation F7 
 
(b) First order Drug Release Kinetics for Formulation F7 
 
(c) Higuchi’s Drug Release Kinetics for Formulation F7 
 
(D) Korsmeyer-Peppa’s Drug Release Kinetics for Formulation 
F7
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Table No.18: Invitro Drug Release of mucoadhesive buccal patches of 
DimenhydrinateF8 
Time in 
hrs 
Log time SQ.RT of 
time 
Abs 
(276nm) 
Cum% 
release 
Log cum% 
release 
0 0.000 0.000 0.000 0.000 0.000 
0.5 -0.301 0.707 0.012 8.62 0.935 
1 0.000 1.000 0.016 11.58 1.063 
2 0.301 1.414 0.022 16.01 1.204 
3 0.477 1.732 0.032 23.36 1.368 
4 0.602 2.000 0.043 31.49 1.498 
5 0.698 2.236 0.065 47.62 1.677 
6 0.778 2.449 0.087 63.90 1.805 
7 0.845 2.645 0.101 74.59 1.872 
8 0.903 2.828 0.111 82.50 1.916 
9 0.954 3.000 0.128 95.52 1.980 
10 1 3.162 0.136 100.75 2.003 
 
Graph No.20: Dissolution profile for Formulation 
F8
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Graph No.21: (a) Zero order Drug Release Kinetics for Formulation F8 
 
(b) First order Drug Release Kinetics for Formulation F8 
 
(c) Higuchi’s Drug Release Kinetics for Formulation F8 
 
(D) Korsmeyer-Peppa’s Drug Release Kinetics for Formulation 
F8
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Table No.19: Invitro Drug Release of mucoadhesive buccal patches of 
DimenhydrinateF9 
Time in 
hrs 
Log time SQ.RT of 
time 
Abs 
(276nm) 
Cum% 
release 
Log cum% 
release 
0 0.000 0.000 0.000 0.000 0.000 
0.5 -0.301 0.707 0.019 13.76 1.138 
1 0.000 1.000 0.026 18.97 1.278 
2 0.301 1.414 0.034 24.96 1.397 
3 0.477 1.732 0.056 41.14 1.614 
4 0.602 2.000 0.078 57.49 1.759 
5 0.698 2.236 0.089 66.03 1.819 
6 0.778 2.449 0.110 81.89 1.913 
7 0.845 2.645 0.118 88.48 1.946 
8 0.903 2.828 0.126 95.13 1.978 
9 0.954 3.000 0.131 99.67 1.998 
 
Graph No.22: Dissolution profile for Formulation F9 
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Graph No.23: (a) Zero order Drug Release Kinetics for Formulation F9 
 
(b) First order Drug Release Kinetics for Formulation F9 
 
(c) Higuchi’s Drug Release Kinetics for Formulation F9 
 
(D) Korsmeyer-Peppa’s Drug Release Kinetics for Formulation 
F9
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Table. No.19: Invitro Drug Release of mucoadhesive buccal patches of 
DimenhydrinateF10 
Time in 
hrs 
Log time SQ.RT of 
time 
Abs 
(276nm) 
Cum% 
release 
Log cum% 
release 
0 0.000 0.000 0.000 0.000 0.000 
0.5 -0.301 0.707 0.017 12.87 1.109 
1 0.000 1.000 0.028 20.14 1.304 
2 0.301 1.414 0.038 27.49 1.439 
3 0.477 1.732 0.054 39.21 1.593 
4 0.602 2.000 0.076 55.32 1.742 
5 0.698 2.236 0.097 70.88 1.850 
6 0.778 2.449 0.112 82.30 1.915 
7 0.845 2.645 0.119 88.10 1.945 
8 0.903 2.828 0.129 96.11 1.982 
9 0.954 3 0.134 100.60 2.002 
 
Graph No.24: Dissolution profile for Formulation F10 
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Graph. No. 25: (a) Zero order Drug Release Kinetics for Formulation F10 
 
(b) First order Drug Release Kinetics for Formulation F10 
 
(c) Higuchi’s Drug Release Kinetics for Formulation F10 
 
(D) Korsmeyer-Peppa’s Drug Release Kinetics for Formulation F10 
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Table No. 20: Cumulative % Drug release of Formulation F1 to F10. 
Time 
Hrs 
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
0.5 11.59 16.4 9.47 10.66 7.92 11.71 11.01 8.62 13.76 12.87 
1 19.67 32.25 16.85 22.86 15.21 16.96 17.73 11.58 18.97 20.14 
2 34.36 46.83 31.58 30.91 21.13 31.78 25.25 16.01 24.96 27.49 
3 44.85 62.98 45.74 46.15 35.75 41.61 39.46 23.36 41.14 39.21 
4 62.68 76.44 54.20 52.30 54.84 66.19 55.27 31.49 57.49 55.32 
5 74.89 82.18 64.93 66.33 64.03 76.37 66.83 47.62 66.03 70.88 
6 83.59 94.39 74.31 81.91 71.14 86.64 81.44 63.90 81.89 82.30 
7 92.37 99.58 85.23 90.53 81.93 92.87 91.78 74.59 88.48 88.10 
8 99.78  90.42 97.8 92.09 99.15 98.54 82.50 95.13 96.11 
9   95.66 100.17 100.18   95.52 99.67 100.60 
10   99.49     100.75   
 
Graph.No.26: Comparative drug release profile for formulation F1 to F10 
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Table No.21: Ex-vivo Drug release of Mucoadhesive Buccal patches of 
Dimenhydrinate (F3) with Porcine Buccal mucosa. 
Time in 
hrs 
Log time SQ.RT of 
time 
Abs 
(276nm) 
Cum% 
release 
Log cum% 
release 
0 0.000 0.000 0.000 0.000 0.000 
0.5 -0.301 0.707 0.072 10.37 0.935 
1 0.000 1.000 0.098 14.33 1.063 
2 0.301 1.414 0.123 18.21 1.204 
3 0.477 1.732 0.165 24.62 1.368 
4 0.602 2.000 0.213 32.02 1.498 
5 0.698 2.236 0.287 43.30 1.677 
6 0.778 2.449 0.362 54.94 1.805 
7 0.845 2.645 0.458 69.82 1.872 
8 0.903 2.828 0.543 83.39 1.916 
9 0.954 3.000 0.567 88.42 1.980 
10 1 3.162 0.574 91.06 2.003 
 
Graph No.27: Ex-vivo Dissolution profile for Formulation 
F3
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Graph. No.28: (a) Zero order Drug Release Kinetics for Formulation F3 
 
(b) First order Drug Release Kinetics for Formulation F3 
 
(c) Higuchi’s Drug Release Kinetics for Formulation F3 
 
(D) Korsmeyer-Peppa’s Drug Release Kinetics for Formulation F3 
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7.8 DRUG RELEASE KINETICS  
Table No. 22: Drug release kinetics: 
Batch 
Zero order 
r
2
 values 
First order 
r
2
 values 
Higuchi 
r
2
 values 
Korsmeyer-
Peppas 
r
2
 values 
‘n’ value 
F1 0.984 0.721 0.966 0.997 0.793 
F2 0.95 0.815 0.989 0.988 0.667 
F3 0.971 0.832 0.978 0.995 0.798 
F4 0.980 0.868 0.964 0.989 0.766 
F5 0.990 0.794 0.944 0.988 0.897 
F6 0.972 0.934 0.953 0.987 0.821 
F7 0.994 0.826 0.939 0.985 0.822 
F8 0.985 0.777 0.889 0.949 0.894 
F9 0.980 0.785 0.955 0.973 0.745 
F10 0.980 0.872 0.956 0.983 0.752 
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Table. No. 23: Model fitting for formulation F3 
 
Mathematical models 
Formulation 
Zero 
order 
First 
order 
Higuchi 
model 
Peppa’s 
model 
‘n’ 
value 
F3 0.971 0.832 0.978 0.995 0.798 
 
 
Table. No. 24: Stability studies after 90 days storage of selected formulation (F3) 
at Room temperature (RT) and 40
0
c and 75%RH 
Storage 
conditions 
Days 
Bio 
adhesive 
strength 
In-vitro 
residence 
time 
Drug 
content 
(mgs) 
Cum% 
drug 
release 
(10hrs) 
30 182 421 3.70 99.41 
60 183 423 3.71 99.02 
Room 
temperature 
90 185 425 3.65 98.67 
30 179 417 3.72 99.45 
60 177 420 3.69 99.08 
At 40
0
c and 
75%RH 
90 175 418 3.62 98.12 
 
 Inference: 
             From the above data it was evident that there was no significant change in the 
physical and performance parameters of Dimenhydrinate buccal patches during the 
stability studies conducted at Room temperature and 40°C & 75%RH for 3 month 
period. 
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FIG.NO.29: SEM PHOTOGRAPH OF FORMULATION F5 
A) SEM photograph of plain buccal patch 
 
 
B) SEMphtograph of buccal patch with 
drug
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6.2. DISCUSSION 
Oral drug delivery system represents one of the frontier areas of controlled 
drug delivery system; such dosage forms are having a major advantage of patient 
compliance. A controlled release matrix dosage form is defined "as one for which the 
drug release characteristics of time course and/or location are chosen to accomplish 
therapeutic or convenience objectives not offered by conventional dosage forms. 
Dimenhydrinate is H1-antagonist used in the Treatment of nausea and 
vomiting caused by drug or motion sickness. The conventional doses release the 
entire drug in just few minutes and therefore the therapeutic concentrations are 
maintained for a short period of time generating a need for administration of another 
dose. Therefore a sustained release formulation of Dimenhydrinate which would 
release the drug over a long period of time is beneficial. 
In the present work efforts have been made to develop the controlled release 
Muccoadhesive buccal patches of Dimenhydrinate prepared by solvent casting 
technique using HPMC E15, HEC, PVA and PVP in different ratios to produce the 
therapeutic dose is needed to be maintained for long time.  
7.1 PREFORMULATION PARAMETERS: 
7.1.1: Determination of  max of Dimenhydrinate: 
On the basis of preliminary identification test it was concluded that the drug 
complied the preliminary identification. From the scanning of drug, it was concluded 
that the drug had 	max of 276 nm, which was equal to 276 nm as reported. Also, an IR 
spectrum was concordant with the reference spectrum of Dimenhydrinate. 
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7.1.2: Preparation of standard calibration curve of Dimenhydrinate: 
From the standard curve of Dimenhydrinate (Table No.7, Graph 6), it was 
observed that the drug obeys beer’s law in concentration range of 1-10 g/ml in 
Distilled water. The linear Regression equation generated was used for the calculation 
of amount of drug. 
7.1.3: Determination of IR spectrum of Dimenhydrinate: 
Physical mixture of drug and polymer was characterized by FT-IR spectral 
analysis for any physical as well as chemical alteration of the drug characteristics. 
From the results, it was concluded that there was no interference in the functional 
group as the principle peaks of the Dimenhydrinate were found to be unaltered in the 
drug-polymer physical mixture, indicating they were compatible chemically. 
7.1.4: Drug excipient compatibility studies: 
Drug-Excipient compatibility studies form an important part of Preformulation 
studies for the determination of interaction between drug and excipient. It is 
determined after storage of specific time period by using suitable analytical 
techniques and the results are indicating that there is no interaction between drug and 
excipients. 
7.2 FORMULATION DESIGN: 
7.2.1: Formulation of the controlled release mucoadhesive buccal patches of 
Dimenhydrinate: 
Total 10 formulations of Muccoadhesive buccal patches were prepared with 
different polymers such as HPMC E15, HEC, PVA and PVP in different Ratios and 
proportions by Solvent casting technique. The prepared Muccoadhesive patches were 
then evaluated for various physico-chemical tests like thickness, folding endurance, 
Chapter-6                                                                                                 Results and discussion 


Dept. of Pharmaceutics, The Erode College of Pharmacy & Research Institute  

 
weight variation, water uptake, bioadhesive strength, drug content uniformity, surface 
p
H
, Mechanical strength, Scanning electron microscopy (SEM), In-vitro release study, 
Invitro residence time, Ex-vivo drug release study, Stability study and Kinetic study.  
EVALUATION PARAMETERS: 
Physical properties: 
Thickness of patch: 
 The thickness of the prepared buccal patches of each formulation was 
determined with in the range of 0.23- 0.26mm.  
Folding endurance: 
The folding endurance of each formulation was determined with in the range 
of 302 to 318. It revealed that good flexibility of patch. 
Mechanical strength: 
Three patches of each formulation were evaluated and mean values are 
recorded in table no.9.1. The values were found to be in the range of 5.28 to 
12.94kg/mm
2
. The values revealed that the patches were having good mechanical 
strength. 
Water uptake study: 
Water uptake of all buccal patches containing Dimenhydrinate is given in 
table no.9.1. The swelling of patch was changes with respect to polymer ratios. The 
values were found to be with in the range of 1.93 to 2.93.it was maximum for F3 i.e. 
2.93. It is revealed that swelling nature of polymer. 
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Performance parameters: 
Content uniformity of active ingredient: 
Table no.9.2 shows the result of drug content uniformity in each formulation. 
Three replicates of each test were carried out. The mean drug content was found to be 
in the range of 3.68 to 3.8 for (each patch size 10mm diameter) the prepared buccal 
patch formulations. It is indicating the uniform distribution of drug in polymer matrix. 
Measurement of bioadhesive strength: 
An effective buccal mucosal device must maintain an intimate contact with 
mucus layer overlying the epithelial tissue. This parameter very important to 
successful utilization of these dosage forms. Hence in-vitro evaluation of buccal 
patches was carried out using porcine gastric mucosa. This gives the indirect 
measurement of bioadhesive strength in grams.  
The maximum bioadhesive strength and force of adhesion was recorded for 
the formulation F3 and the values were 187.67 and 1.82 respectively. 
The Invitro residence time was recorded and the values were changing with 
different ratios of polymers and the maximum for F3 about 490 mins. 
Measurement of surface P
H
 :  
They were found to be with in the range of 6.3 to 6.6 for all formulations and 
were almost with in the range of salivary p
H
 i.e. 6.2 to 7.4. There was no considerable 
difference in surface p
H
 of patches. It represents the better patient acceptability. 
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In vitro release study: 
The in-vitro dissolution was studied in phosphate buffer p
H
 6.8. The Invitro 
dissolution studies were carried out in triplicate and the results shown in the tables are 
mean of the replicate values. The Invitro released data obtained for patches F1 to F10 
are tabulated in table no.10 to 19 respectively. The maximum release was observed in 
F3 formulation, it was up to 10 hours. The release is due to the uniform and proper 
mixing of drug and polymers which enables the drug to release in steady state 
manner. 
Criteria for optimization: 
The formulation F3 is optimized on the basis of Invitro drug release, swelling 
index, long Invitro residence time and good bioadhesive strength. The Ex-vivo release 
studies were performed by using 7.4 P
H 
saline phosphate buffer for formulation F3 by 
using porcine buccal mucosa as a model membrane and it was shown that good drug 
permeability across the membrane above 10 hours. 
Stability study: 
Stability studies of  the prepared buccal patches were carried out, by storing 
formulations F3 at, room temperature and humidity and 40
0
 C±2
0
C/ 75%RH ± 5% RH 
in humidity control oven for ninety days. Stability studies were carried out to predict 
the degradation that may occur over prolonged periods of storage at various 
temperatures and humidity for formulations F3 over a period of 90 days. The results 
of the stability studies, which were conducted for 90 days, are shown in table no.24. 
The result obtained showed a slight decrease in, in vitro release of formulations F3 as 
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compared to the fresh formulations F3. The shelf life of the fabricated device was 
calculated based on these parameters. 
Kinetic study: 
        To study the drug release kinetics, data obtained from In-Vitro drug release 
studies are plotted in various kinetic models. The curve fitting results of the release 
rate profile of the designed formulations gave an idea on the mechanism of drug 
release. 
Based on the “n” values are ranging from 0.745-0.893 for all the formulations 
formulation, the drug release was found to follow Anomalous (non-Fickian) diffusion. 
This value indicates a coupling of the diffusion and erosion mechanism (Anomalous 
diffusion) and indicates that the drug release was controlled by more than one process.  
Also, the drug release mechanism was best explained by zero order, as the plots 
showed the highest linearity (r2 = 0.971), as the drug release was best fitted in zero 
order kinetics, it indicated that the rate of drug release is concentration independent.  
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7. SUMMARY AND CONCLUSION 
7.1 Summary: 
Dimenhydrinate is a H1 Antagonist; it is used in the treatment of vomiting 
caused by motion sickness. 
As the conventional doses release the Dimenhydrinate in just few minutes and 
therefore the therapeutic concentrations are maintained for a short period of time 
generating a need for administration of another dose. Therefore an attempt was made 
to maintain the therapeutic concentration for longer period of time. This was achieved 
by developing controlled release drug delivery system. 
These controlled release Muccoadhesive buccal patches mainly prepared for 
release of the drug for longer period of time i.e., 10 hours and utilizing the drug to full 
extent avoiding unnecessary frequency of dosing. 
For the formulation of Muccoadhesive buccal patches HPMC E15, HEC, PVA 
and PVP were used as matrix forming agents. Other excipients used are Propylene 
glycol as a plasticizer. Fourier transform Infrared spectroscopy confirmed the absence 
of any drug/polymers/excipients interactions. 
The Muccoadhesive buccal patches were prepared by solvent casting method 
using magnetic stirrer. The prepared controlled release Muccoadhesive buccal patches 
were evaluated for  thickness, folding endurance, weight variation, water uptake, 
bioadhesive strength, drug content uniformity, surface p
H
, Mechanical strength, 
Scanning electron microscopy (SEM), In-vitro release study, Invitro residence time, 
Ex-vivo drug release study, Stability study and Kinetic study.  
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 Formulation F3 showed good Bioadhesive strength and a controlled drug 
release and also shown good result for all other parameters when compared with all 
other formulations. Hence formulation F3 is considered to be the optimized 
formulation. Stability studies were carried out for F3 formulation they had showed 
good stability when stored at accelerated stability state as per the ICH guideline and 
the values were with in a permissible limits. 
It was observed that Formulations F3 retained the drug release up to 24 hrs. 
All formulations were subjected for four different models viz. Zero order, First order, 
Higuchi matrix and Peppas model equations and all the formulations best fit in to the 
Peppas model by giving the values of diffusional exponent (n) in the range of 0.6-0.9 
that indicate the formulation had release the drug by diffusion followed by erosion 
mechanism. 
It was revealed that polymer ratios had significant influence on drug release. 
Thus conclusion can be made that stable dosage form can be developed for 
Dimenhydrinate for controlled release by buccal patches. 
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7.2 CONCLUSION 
In the present study, an attempt has been done to develop a novel 
muccoadhesive drug delivery system in the form of the buccal patches for the release 
of Dimenhydrinate in a bidirectional manner, to maintain constant therapeutic levels 
of the drug for long time. 
Buccal formulations of Dimenhydrinate in the form of muccoadhesive patches 
were developed to a satisfactory level in term of drug release, bioadhesive strength, 
content uniformity, percentage water uptake, surface P
H
, thickness and mechanical 
strength. 
Although all buccal patches exhibited satisfactory results, best results were 
obtained with optimized formulation F3 containing HPMC and HEC in 1:3 ratios. 
Invitro dissolution studies of the optimized formulation showed that the percentage 
cumulative drug release about the release of Dimenhydrinate from the patches in the 
present work appeared to occur due to diffusion and erosion mechanism. The release 
pattern was found to be non-Fickian. 
The above study concluded that the possibility of the making of mucoadhesive 
drug delivery system for Dimenhydrinate which will be more efficacious and 
acceptable than conventional drug delivery of Dimenhydrinate and also having 
satisfactory controlled release profile which may provide an increased therapeutic 
efficacy.  

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